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~ The cutlass represents Grandfather George's career in agriculture and irrigation. 
~ The needle represents Grandmother Edna's lustrous career as a seamstress. 
~ Inspired by the location of the family's home in West Coast Berbice, the grass depicts the savannahs of 
Eldorado and Belladrum. 
~ The African inspired shield symbolizes protection and defense of the family. 
~ The colors used to bring life to the crest are loosely based on the five colors (yellow, red, green, white and 
black) of the Golden Arrow Head (the Guyana Flag). 
~ Finally, the meanings of the Adinkra symbols (Ghanaian/West African) on the shield are listed below and are 
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 dependent, human dopamine (DA) and norepinephrine (NE) transporters (hDAT 
and hNET, respectively) control the duration of DA and NE neurotransmission by taking up 
extracellular neurotransmitter.  Through outward and inward conformational transitions, DAT 
and NET work as pumps to transport substrates and ions between extracellular and intracellular 
environments.  To study DAT and NET conformations, we mutated the threonine (Thr, T) 
residue within a conserved RETW sequence, which is juxtaposed to transmembrane domain 1a 
that is essential for ligand binding.  Since the Thr residue is a putative phosphorylation site, it 
was mutated to alanine (Ala) (DAT, T62A; NET, T58A), or aspartate (Asp) (DAT, T62D; NET, 
T58D) to mimic a non-phosphorylated and phosphorylated state, respectively.  Studies in 
heterologous HEK293 cells revealed the Thr (T) to Asp (D) mutation profoundly shifts the 
transporter from a predominately outward to inward orientation that exhibits reduced uptake but 
enhanced baseline reverse transport of substrate compared to wild type.  Thr to Ala (A) mutants 
mostly functioned like wild type.  A consequence of the predominantly inward conformation was 
an enhanced affinity for all substrates tested in the T to D mutants, with varying impacts of 
inhibitors.  In further investigations, T62D-hDAT demonstrated wild type inward transport and 
retention of substrate when the substrate was not subject to reverse transport.  These data showed 
that an inward-facing transporter can complete the entire transport cycle, even though it prefers 
an open inward-gate.  Altering the transmembrane Na
+
 gradient revealed that the Thr to Asp 
mutation renders the mutant in a conformation mimicking that promoted by the Na
+
 gradient to 
elicit reverse transport.  This is also the conformation elicited by amphetamine, an abused 
psychostimulant and transporter substrate.  This suggests the T to D mutation mimics 




importance of juxtamembrane mutations to the conformation of DAT and NET, as well as 
knowledge of the responsiveness of transporter conformations to ligands and, crucially, to 
membrane gradients.  This work demonstrates that the transporter, despite being a pump, can 








Dopaminergic and Noradrenergic Systems 
Dopamine (DA) and norepinephrine (NE) are amongst the catecholamine class of 
neurotransmitters that have important functions within the central nervous system.  In the brain, 
the NE projections originate from the locus ceruleus and project throughout the frontal and 
cerebral cortex and thalamus.  Behaviors involving signaling through these neurons include 
anxiety, arousal, and fear.  NE also has important actions in the periphery and autonomic nervous 
system.  There are 3 main dopaminergic pathways.  The nigrostriatal pathway projects from the 
substantia nigra to the striatum and is largely involved in controlling movement.  Dopamine 
neurons within the nigrostriatal pathway are degenerated in Parkinson’s disease patients.  
Neurons with cell bodies originating in the ventral tegmental area project to the prefrontal cortex 
in the mesocortical system and to the nucleus accumbens in mesolimbic pathway.  Signaling 
through these projections mediates effects such as cognition, emotion, and motivation (Gnegy, 
2012; Meyer and Quenzer, 2005).  These DA projections are a key component of drug abuse, 
particularly the reward and salience associated with drug taking (Robinson and Berridge, 2003).   
The rate-limiting step in DA and NE synthesis is the conversion of the amino acid tyrosine to L-
DOPA via tyrosine hydroxylase.  DA is synthesized from the L-DOPA precursor by aromatic L-
amino acid decarboxylase.  Noradrenergic neurons and adrenal glands contain the enzymes 




neurotransmitters are stored in synaptic vesicles.  Neurotransmitters are taken up into vesicles via 
vesicular monoamine transporters (VMAT2) by a H
+
 antiport driven mechanism.  Packaging of 
neurotransmitters into vesicles protects them from degradation by the metabolic enzymes 
catecholamine-O-methyl transferase (COMT) and monoamine oxidases (MAO).  Several 
metabolites are produced from the breakdown of DA and NE by COMT and MAO.  Drugs that 
inhibit COMT and MAO block catecholamine metabolism and have therapeutic relevance and/or 
contraindications with other medications (Brunton et al., 2006; Gnegy, 2012; Meyer and 
Quenzer, 2005). 
Neuronal activation by the generation of an action potential depolarizes the membrane and 
stimulates vesicles to fuse with the presynaptic membrane and release neurotransmitter into the 
extracellular space (Rizo and Rosenmund, 2008).  The concentration of neurotransmitter present 
in the synaptic cleft, and thus neurotransmission, is regulated by spontaneous diffusion, 
metabolism, and reuptake of the neurotransmitter (Giros and Caron, 1993; Leviel, 2011).  The 
dopamine and norepinephrine transporters (DAT and NET, respectively) are presynaptic 
membrane proteins that have a pivotal role in decreasing the content of extracellular 









DAT & NET Structure and Function 
Structure 
The monoamine transporter family includes DAT, NET and the serotonin (5-HT) transporter 
(SERT).  These transporters belong to the SLC6A gene family, which includes a wide array of 
transporters that are expressed throughout the brain and periphery (Chen et al., 2004c; Hahn and 
Blakely, 2007).  DAT and NET have 12 transmembrane (TM) spanning domains with alternating 
intra- and extracellular loops (IL, EL) and intracellular amino (N-) and carboxyl (C-) termini 
(Giros and Caron, 1993; Sucic and Bryan-Lluka, 2005) (Figure 1-2).  These regions contain 
consensus sites for protein regulation such as glycosylation (EL 2), ubiquitination (N-terminus), 
and phosphorylation (N- and C- termini, ILs).  These processes regulate a range of transporter 
properties that include membrane expression, distribution or trafficking (recycling and 






 Figure 1-2. Amino acid sequence and transmembrane topology of (top) DAT and (bottom) NET, 





Neurotransmitter uptake  
Transporters of the SLC6A gene family couple substrate translocation with ion movement.  The 
high extracellular sodium (Na
+
) concentration, along with chloride (Cl
-
), provides the energy for 
substrate transport (Hahn and Blakely, 2007).  In the case of SERT, potassium is also counter-
exchanged during 5-HT transport (Rudnick, 1998).  The major function of transporters is to 
remove substrate from the extracellular space, which means that the transporter serves as a 
critical component to terminating synaptic signaling.  DAT knockout mice demonstrate 
hyperlocomotor activity due to markedly increased extracellular levels of DA (Giros et al., 
1996).  The complexity of DAT homeostasis is exemplified by the myriad interacting proteins 
that influence transporter function termed as the DAT proteome (Torres, 2006).  DAT interacting 
proteins within the proteome include, but are not limited to syntaxin 1a, Rack1, synuclein, Hic-5, 
and Pick-1, which bind either the N- or C-terminus of DAT (Torres, 2006).  In addition, 
trafficking of DAT to (recycling) and from (endocytosis) the plasma membrane is regulated on a 
constitutive basis and by substrates themselves as well as other neurotransmitters (Furman et al., 
2009; Johnson et al., 2005a; Melikian, 2004).   
Monoamine transporters are targeted by a number of drugs, both therapeutic agents and drugs of 
abuse.  Many inhibit reuptake which results in increased extracellular levels of neurotransmitter 
available for postsynaptic activation.  For instance, inhibitors that selectively block the uptake of 
serotonin and norepinephrine through SERT and NET, respectively, are mainline therapies for 




like cocaine and amphetamine (AMPH) also act upon monoamine transporters to increase 
neurotransmitter content in the synapse.  The binding site for cocaine within DAT is predicted to 
overlap with the site for DA (Beuming et al., 2008), resulting in competitive blockade of DA 
uptake.  Although it shares structural similarity to amphetamines, methylphenidate (Ritalin) acts 
much like cocaine in that it blocks the DAT.  Methylphenidate is clinically used to treat attention 
deficit hyperactivity disorder (ADHD) (Volkow et al., 2001).  Another pharmaceutical drug, 
Adderall is a low dose, racemic mixture of d- (active) and l- (inactive) AMPH that is used for the 
treatment of ADHD and narcolepsy.  However, higher doses of AMPH oversaturate the 
dopaminergic system, which is an important factor in the rewarding, reinforcing, and salient 
(wanting) properties associated with drug taking and abuse (Howell and Kimmel, 2008; 
Robinson and Berridge, 2003).  The effects of AMPH (and the more potent methamphetamine) 
are substantively different from other drugs affecting the transporter because AMPH is a DAT 
substrate and the increased extracellular DA levels occur by a combination of actions.  These 
include: 1) competing for neurotransmitter reuptake, 2) disrupting vesicular DA storage, and 3) 
stimulating reverse transport of DA (Sulzer et al., 2005).   
Neurotransmitter efflux – reverse transport 
AMPH is a phenylethylamine and closely related to the native structure of catecholamines; 
however it lacks the hydroxyl groups on the benzene ring that classify it as a catecholamine.  The 
mechanism of AMPH action on the transporter is unique and a subject of intense study.  




counteracted by movement of DA out of the cell (Fischer and Cho, 1979).  However, other 
factors have been demonstrated to be involved in AMPH-stimulated efflux.   Sitte et al. (1998) 
demonstrated a poor correlation between substrate-induced release and transport.  In comparison 
to DA, AMPH had a lower rate of uptake, but increased potency to stimulate release of the 
substrate MPP
+
 in DAT-transfected HEK 293 cells.  Instead, substrate-induced release rates were 
in accordance with their ability to induce inward currents (Sitte et al., 1998) (see Transporter 
associated currents section).  Transporter trafficking also influences efflux and uptake through 
DAT (Robertson et al., 2009).  Both DA and AMPH have biphasic effects on DAT surface 
expression in cells or rat brain preparations from the striatum.  Rapid stimulation with AMPH (< 
1min) resulted in increased surface DAT and DA efflux without affecting DA influx (Furman et 
al., 2009; Johnson et al., 2005a).  Observed unparalleled changes in the uptake and efflux 
properties of DAT suggest that facilitated diffusion is not the sole explanation for the mechanism 
of AMPH-induced DA efflux through DAT.   
Another component of AMPH-stimulated DA efflux is its action on synaptic vesicles.  Once 
inside the presynaptic terminal AMPH is taken up by vesicular monoamine transporter (VMAT)-
2 and results in displacement of vesicular contents and elevation of cytosolic DA.  An 
explanation for this is the weak base theory of AMPH action (Sulzer et al., 2005).  As a weak 
base, AMPH would reduce the intracellular pH of vesicles, decreasing DA uptake into the 
vesicle while increasing the cytosolic DA available for release.  A major challenge to this theory 
includes the ability of AMPH to stimulate efflux after vesicular depletion of neurotransmitter 




Weissman et al., 1966).  These works underscores that AMPH requires newly synthesized DA 
and elevation of cytosolic DA alone is not enough to stimulate reverse transport.  In fact both the 
exchange diffusion and vesicular depletion mechanisms are important for AMPH-induced DA 
release through DAT (Jones et al., 1998).  
As further explained in the following section on the transport model, sodium and chloride are 
inwardly transported along with the catecholamine.  In fact, evidence demonstrates that the 
increase in intracellular Na
+
 provides the driving force for rebinding of DA and reversal of the 





 ATPase results in elevated DA and NE efflux due to increased intracellular Na
+
 levels 
(Langeloh et al., 1987; Liang and Rutledge, 1982).  Although AMPH-stimulated efflux requires 
interaction and transport of AMPH through DAT (Jones et al., 1998), in heterologous cells it has 
been shown that elevation of intracellular Na
+
, independent of AMPH, is sufficient to drive DA 
efflux (Khoshbouei et al., 2003). 
The medical availability of AMPH for its therapeutic applications contributes to its misuse and 
abuse.  Elucidating the molecular mechanisms behind AMPH-induced DA efflux is important to 
understand monoamine transporters and identify potential cellular targets to reduce the abuse 
liability of amphetamines. 
Transport model 
The alternating access model posits that the transporter transitions between outward- and inward-




outward facing conformation, ligand (substrate and co-transported ions) binding is accessible 
from the extracellular side of the membrane.  Binding of substrate and ions stimulates the 
transporter to assume the inward facing conformation so that ligands are released on the 
intracellular side of the membrane.  Intricate studies over the past decade have demonstrated that 
although the outward and inward facing conformations are the beginning and end stages of 
transport, there are other intermediate interactions and movements involved in the transport 
process, as well. 
Bacterial Sodium Symporter Homologue, LeuT 
Crystallization of the Aquifex aeolicus bacteria leucine transporter (LeuT) (Krishnamurthy and 
Gouaux, 2012; Yamashita et al., 2005), in combination with molecular modeling and 





 dependent transporter family.  The first crystal structure of LeuT was obtained in the 
substrate occluded state with 2 Na
+
 and 1 Leu molecule positioned in their binding sites (Figure 







 Figure 1-3. Proposed transport mechanism derived from the crystallization of LeuT in the substrate 
 occluded state (top) (Yamashita et al., 2005). Outward-open, substrate-occluded, and inward-open crystal 





Unlike eukaryotic transporters, transport via LeuT is chloride independent (Zomot et al., 2007).  
As a whole, the homology between LeuT and eukaryotic monoamine transporters is relatively 
low.  However, the greatest density of conserved residues lies within TMs 1 and 6.  These two 
TMs are positioned in an anti-parallel orientation and are separated into two segments by 
unwound alpha helices (TM 1a and 1b; TM 6a and 6b).  The unwound regions of TM 1 and 6 
along with TM 3 and 8 form the LeuT ligand binding pocket for substrate leucine and two 
sodium ions  (Figure 1-3) (Yamashita et al., 2005).  Binding of substrate and co-transported ions
 
involves a complex network of interactions between amino acid residues of TM domains, ILs, 
ELs and the ligands.  
Transporter conformations & gating mechanisms 
Numerous studies have investigated the molecular mechanism of reuptake.  Transport of 
substrates between the extracellular and intracellular environments is controlled by intricate 
gating mechanisms.  The process involves a complex coordination between the substrates 





water molecules.  To understand the gating mechanisms, it is important to also discuss the 
different transporter conformations in more detail.  The transporter transitions between 4 main 
conformational states: outward-open, outward-occluded, inward-open, and inward-occluded.  
Although crystal structures do no yet exist for DAT and NET, the first 3 conformations have 
been successfully crystallized for LeuT (Krishnamurthy and Gouaux, 2012; Yamashita et al., 




6-10 are inverted repeats with similar structural arrangement (Yamashita et al., 2005).  This 
finding gave rise to the rocking bundle mechanism of transport that was based upon swapping 
the conformations of the repeats (Forrest and Rudnick, 2009).  By this model, the four-helix 
bundle (TMs 1, 2, 6 and 7) within the repeats would “rock” to open and close access to the 
binding site from the alternating orientations.  Later modeling (Shan et al., 2011) and 
crystallization (Krishnamurthy and Gouaux, 2012) of LeuT in the inward facing state revealed 
that intracellular exposure of the permeation pathway relies more on a remodeling of network of 
interactions rather than rigid motions based on transmembrane symmetry.   
The proposed transport mechanism derived from the LeuT crystal structure is paramount in our 
understanding of how the transport cycle operates in related monoamine transporters.  The 
population of transporter at the presynaptic membrane could be in any given state at a particular 
time.  However, for ease of the description here will start and end with the outward-open and 
inward-open states, keeping in mind the transport mechanism involves full cycling (outward-
inward, inward-outward).  The segments of the LeuT have been described as having 2 domains 
called the scaffold and core.  The scaffold domain consists of TMs 3, 4, 8, 9 and 10; while the 
core domain is comprised of TMs 1, 2, 6 and 7.  In the absence of substrate the transporter is in 
an outward-open state that is maintained by the high extracellular sodium concentration.  The 
extracellular gate is comprised of TMs 1b and 6a of the core domain, which are positioned 
outward and away from the scaffold domain (Figure 1-5) (Krishnamurthy and Gouaux, 2012).  In 
the absence of substrate, the permeation pathway of the transporter is closed.  This is deemed the 




molecules from the extracellular space (Yamashita et al., 2005).  Sodium binding initiates the 
transport cycle by increasing the entry of water, and primes the transporter for substrate binding 
(Shi et al., 2008).  When substrate is bound, the extracellular gate closes by bridging residues in 
TMs 1b and 6a with residues in TM 3 and 10.  These stable interactions put the transporter in the 
outward-occluded state where substrate is securely ‘locked’ in its binding site (Yamashita et al., 
2005).  As water molecules carry substrate through the permeation pathway, extracellular gating 
interactions are stabilized while inner networks are disrupted.  The inward-open state is achieved 
when the intracellular gate, formed by TM segments 1a and 6b, opens to allow release of 
substrate and Na
+
 inside the cell.  Relative to other movements, the inner gate undergoes the 
largest structural shift during the transport cycle (Shan et al., 2011; Zhao et al., 2012).  The 
inward-occluded state is presumed to occur during the transition of the transporter back to the 
outward-open state.  However, there is no crystal structure of the inward-occluded state 
(Krishnamurthy and Gouaux, 2012), and the details of this transition are not well known. 
Sodium and substrate binding sites 
 The requirement for sodium ion binding to transporter is well known; and presence of 2 Na
+
 
binding sites, termed Na1, Na2, are modeled from the LeuT crystal structure (Yamashita et al., 
2005).  However, a developing theory postulates the presence of two substrate binding sites 
termed S1 and S2, within the DAT and NET.  S1 and S2 were identified from the occluded LeuT 
crystal structure and steered molecular dynamic (SMD) simulations studying ligand movement 




binding pocket) of the transporter.  The presence of Na
+
 in the Na1 and Na2 sites are deemed 
necessary to stabilize the core, unwound regions of TM 1 and TM 6, and bound substrate (Leu) 
molecule.  The S1 site is located deep within the central binding pocket at the unwound regions 
of TM 1 and 6.  Substrate in the S1 site directly interacts with the sodium in the Na1 site 
(Yamashita et al., 2005).  Upon occupation of the S1 site, binding of substrate in S2 serves as an 
allosteric trigger for the release of Na
+
 and S1 substrate into the intracellular space (Shi et al., 
2008; Zhao et al., 2011).  Inhibitors like tricyclic antidepressants (TCAs) bind at the extracellular 
vestibule, stabilizing the extracellular gate and closed conformation to prevent transport and 
competitively block binding of substrate to the S2 site to inhibit transport (Singh et al., 2007; 
Zhao et al., 2010; Zhou et al., 2007). 
The modeling studies discussed above for the proposed “substrate-driven allosteric mechanism” 
of the S1, S2 transport model (Shan et al., 2011) are compelling yet somewhat puzzling, given 
that they are inconsistent with long standing stoichiometry predictions of substrate/ion ratios of 
monoamine transporters.  Consequently, additional studies have challenged the existence of an 
S2 site.  Binding analyses of WT LeuT in comparison to mutants of the proposed S2 site refute 
the secondary site model and support a single high-affinity substrate site (Piscitelli et al., 2010).  
Furthermore, Krishnamurthy and Gouaux (2012) used a combination of mutagenesis and 
antibody based techniques to provide additional X-ray crystal structures of LeuT in the outward-
open and inward-open conformational states (Krishnamurthy and Gouaux, 2012).  Recall, the 
original LeuT crystal structure was obtained in the intermediate occluded state (also called 




structures for the LeuT orientations before binding of extracellular substrate (outward-open) and 
after ligand release to the intracellular space (inward-open).  According to their data, as depicted 
in Figure 1-3, binding of substrate and sodium molecules in the core region closes off the 
extracellular pathway by EL 4 “packing tightly against TM 1b and TM 7 on one side and TM 3, 
TM 8 and EL 12 on the other side”  (Krishnamurthy and Gouaux, 2012).  The postulated S2 site, 
which include residues Ile 111 and Leu 400 would be deeply buried, thus inaccessible to bind a 
second substrate molecule.  Instead, they postulate that the extracellular gate closes via formation 
of interactions between TM1b, 6a, 10, 11, and EL 4 while a disruption of interactions between 
TMs 1a, 6b, 8, and the N-terminus (NT) opens the intracellular gate.  This triggers release of 
ligands to the intracellular space, instead of allosteric changes caused by substrate binding in S2 
model.  Transporter inhibitors block the collapse of EL 4, thus preventing the opening of the 
intracellular gate and arresting the transporter in the outward facing orientation (Krishnamurthy 
and Gouaux, 2012). 
A recent molecular modeling study of SERT also disagrees with the existence of a second 
substrate site.  According to their simulations, Koldso et al. (2011) found that substrate 
occupation of an S2 site did not produce transport associated conformational changes.  Notably, 
they also modeled sodium dissociation from the Na2 site triggering intracellular substrate 
release, thus refuting the notion of intracellular substrate (S1) release coming from S2 substrate 
binding in the Shan et al. (2011) allosteric mechanism. Na2 trigger of intracellular S1 release 
was further supported by a significant increase in the Km for Na
+
 to stimulate serotonin uptake in 
a SERT Na2 site mutant, indicating more Na
+




the uptake assay in cells without Na2 compared to WT (Koldso et al., 2011).  This finding is in 
line with the “first-in, first-out” model for hDAT function where Na
+
 binding and unbinding 
precedes AMPH during the outward (extracellular) to inward (intracellular) transition of DAT 
(Erreger et al., 2008). 
Perhaps the inconsistency for the existence of the S2 site lies within variation of experimental 
conditions (Quick et al., 2012) and methods (high affinity binding, simulation modeling, and 
crystallography) utilized.  Despite the discrepancy for the presence or absence of an S2 site in 
these models, it is agreed upon that extracellular and intracellular molecular networks are vital 
components that mediate the global conformational changes of the transporter.  Regardless of the 
S2 debate, the information from LeuT structures and models has been extended towards 
understanding corresponding residues regulate transport within DAT and NET (for which crystal 
structures are not available).  Various studies have combined modeling simulations and 
transporter mutagenesis to learn more about the specific roles of particular DAT and NET amino 
acids. 
Dopamine transporter mutants  
Residues throughout DAT have been implicated in maintaining normal transporter functions and 
orientation.  Many studies have used site-directed mutagenesis to probe the role of various amino 
acid residues in transporter function.  This involves using PCR to generate single or multiple 
point mutations and transiently or stably expressing the sequence-confirmed mutant transporter 




and reverse transport are tested in the mutants and compared to cells containing normal, wildtype 
(WT) transporter.  Numerous DAT mutants have been used to study the impact of particular 
residues on functional characteristics and/or conformational preference of the transporter.  Some 
mutations have exhibited differential effects on inward versus outward DA transport.  For 
instance, the S528A DAT mutant (TM 11) showed an enhanced rate of DA efflux but similar DA 
uptake kinetics in comparison to WT DAT (Chen and Justice, 2000).  Alanine substitution of 
proline 572 of TM 12 displayed increased DA efflux and reduced the dependence for sodium and 
chloride ions to stimulate DA release (Itokawa et al., 2002).  While most experimental 
mutagenesis studies have evaluated engineered mutations, naturally occurring DAT variants 
exist that also change transporter properties (Mazei-Robison and Blakely, 2005).  In particular, 
the rare hDAT A559V variant in TM 12 was discovered in two male ADHD patients and one 
female patient with bipolar disorder.  Analysis of this mutant in a heterologous cell based system 
revealed a spontaneous DA efflux attributed to an increased sensitivity for intracellular Na
+
.  The 
A559V mutant displayed normal DAT surface expression and DA uptake in comparison to WT 
hDAT (Mazei-Robison et al., 2008).  Experiments with transporter mutants can also provide 
structural insights in addition to translocation information. 
Outward facing DAT mutants were created by mutating the tryptophan 84 to leucine (W84L) of 
TM 1 or aspartate 313 to asparagine (D313N) within TM 6.  Both W84L and D313N mutations 
enhanced binding of the cocaine analog CFT (2b-carbomethoxy-3b-(4-fluorophenyl)tropane) 
(Liang et al., 2009; Lin et al., 2000).  These mutants have also been used to study the Na
+
 




several studies have identified residues that place DAT in a predominately inward facing 
orientation.  These include Y335A (IL 3/TM 6) (Loland et al., 2002), K264A (IL 2/TM 5), 
D436A (IL 4) (Loland et al., 2004), D345A (Loland et al., 2004) and D345N (IL3) (Chen et al., 
2004a).  Characteristics of the inward facing DAT mutants are a low capacity for DA uptake, 
reduced affinity for inhibitors, and enhanced substrate affinity (Chen et al., 2004a; Loland et al., 
2002).  Interestingly, the deficits demonstrated by Y335A and D345N mutants can be rescued by 
Zn
2+
 (Chen et al., 2004a; Loland et al., 2002).  The extracellular face of DAT has 3 endogenous 
zinc binding coordination sites, H193 in EL 2 and H375 and E396, both in EL 4 (Loland et al., 
1999; Norregaard et al., 1998).  Zinc binding to DAT does not obstruct binding of DA, but 
reduces DA uptake in WT DAT.  It is thought that zinc stabilizes the outward facing 
conformation of WT DAT and prevents the formation of other conformational states required for 
DA translocation (Norregaard et al., 1998).  Although, Pifl et al. (2009) determined that the 
inhibitory or stimulatory action of Zn
2+
 depends on whether the membrane potential is below or 
above the reversal potential for Cl
-
.  Zinc effects are not observed in NET due to the lack of 
H193 at the equivalent NET position, but were upon mutation of the corresponding K189 residue 
to histidine (Norregaard et al., 1998).  The studies mentioned here and many others have shed 





The conserved RETW sequence 
A number of putative regulatory sites are present in the N-terminus of the transporter as 
highlighted in the alignment of the N-termini of DAT, NET, and SERT shown in Figure 1-4 
(Vaughan, 2004). 
 
 Figure 1-4. N-terminal alignment of human (h) and rat (r) DAT, NET and SERT ending before TM 
 1. Putative phosphorylation sites for serine (red), threonine (blue), and tyrosine (green) are highlighted 
 (Vaughan, 2004). 
   
Various studies have linked sites of the DAT N-terminus to modulation of transporter functions 
and AMPH-induced DA efflux, in particular. For instance, the N-terminal truncation of the first 
22 amino acids of DAT significantly reduced AMPH-stimulated DA efflux, which was attributed 
to lack of phosphorylation at serine residues 7 and 12 (Khoshbouei et al., 2004).  As found some 
years later, the first 33 amino acids of the N-terminus were required for the SNARE protein 
syntaxin 1A to interact with DAT, and this association increased AMPH-induced efflux in a 
CAMKII dependent manner (Binda et al., 2008).   Interestingly, AMPH also increases the 
interaction of syntaxin 1A with the NET N-terminus (Dipace et al., 2007), and induces reverse 




implicated in DA efflux via DAT (Figure 1-4), which points towards the involvement of 
additional transporter regions mediating AMPH actions. 
The RETW motif at the distal end of the N-terminus is conserved amongst all monoamine 
transporters (Figure 1-4) (Vaughan, 2004).  The short N-terminus of LeuT also contains the 
RE*H motif although His replaces the Thr residue (Yamashita et al., 2005).  This sequence is 
located just before the start of TM1a, which is a critical component of the ligand binding region 
(Yamashita et al., 2005) and involved in the largest movements during transport (Shan et al., 
2011).  RETW is a canonical phosphorylation sequence for a variety of protein kinases including 
PKA and PKC (Giros and Caron, 1993; Vaughan, 2004).  Phosphorylation is a highly 
investigated yet complex posttranslational modification of transporter trafficking and functional 
activity (Schmitt and Reith, 2010; Vaughan, 2004). Our laboratory has identified the β isoform 
of protein kinase C (PKCβ) as a key regulator of DAT trafficking and AMPH-induced DA efflux 
(Chen et al., 2009; Furman et al., 2009; Johnson et al., 2005b).  Due to its putative 
phosphorylation and high conservation amongst all monoamine transporters (Giros and Caron, 
1993; Vaughan, 2004), the Thr residue within the RETW sequence was an ideal candidate to 
explore for additional regions involved in dopamine efflux.  Alanine and aspartate mutations 
were made to position 62 of hDAT to mimic a non-phosphorylated (T62A) and phosphorylated 
(T62D) state at this site.  Previous work established the T62A hDAT mutant was similar to WT.  
However, T62D hDAT is an inward facing mutant based upon some hallmark characteristics of 
an inward transporter discussed above.  This conclusion was based upon reduced [
3
H]DA uptake 
and abrogated AMPH-stimulated [
3
H]DA efflux combined with elevated basal [
3




The altered characteristics of T62D hDAT were partially restored by zinc, further indicating a 
shift in transporter orientation in this mutant (Guptaroy et al., 2009).  Work discussed in chapter 
2 of this dissertation further assessed the effects of the Thr 62 DAT and corresponding Thr 58 
NET mutations on substrate and inhibitor interactions with the transporter (Guptaroy et al., 
2011). 
The involvement of other residues within the RETW sequence on conformational changes has 
been made evident through a variety of mutagenesis, crystallography, and simulation modeling 
studies.  Using computational analysis, the N-terminal Arg 60 (LeuT, R5) of the DAT RETW 
was shown to participate in a network of interactions with residues of IL 3, TM 6, and TM 8 that 
regulate intracellular access to the substrate binding site.  The Arg 60 residue forms a salt bridge 
with Asp 436 (LeuT, D369) that is stabilized through its catonic-ᴨ interaction with residue Tyr 
335 (LeuT, Y268) (Kniazeff et al., 2008).  As discussed earlier, disruption of the intracellular 
interaction network contributes to formation of the inward-facing state (Krishnamurthy and 
Gouaux, 2012; Zhao et al., 2012; Zhao et al., 2010).  The inward orientation is thought to occur 
by a change in residue binding partners during the transition from the outward-occluded to 
inward-open states.  According to a recent simulation study, DAT Tyr 335 (TM 6) forms a 
hydrogen bond with Glu 428 (TM 8) when substrate is bound in the S1 site and the intracellular 
gate is closed.  In the inward-facing state, Y335 binds to Thr 62 residue of the RETW sequence.  
The change in Y335 interactions is thought to facilitate the opening of the intracellular gate and 





 Figure 1-5. Changes in the intracellular gating network of DAT. A. View of the closed intracellular 
 gate in outward-facing S1 bound DAT (orange); B. Inward-facing DAT (teal) with intracellular gate open 
 (Shan et al., 2011).  
 
Transporter associated currents 
Transport through DAT and NET involves the movement of sodium, chloride, and substrate.  
There is a positive net flux of charge exchange, making the transport of substrate, from outside to 
inside the cell, an electrogenic process.  Measurable currents are therefore generated due to the 
exchange of ions across the plasma membrane.  Electrophysiological properties and the influence 
of pharmacological agents are studied in transporter expression systems using voltage clamp 
techniques.  Currents can be measured in a variety of transporter-expressing systems including 
neuronal cultures, heterologous cells or Xenopus laevis oocytes.  Transporter mediated currents 




Stoichiometry of ion flux during transport 





), and potassium (K
+
) provide the energy to carry substrates against 
their concentration gradients (Hahn and Blakely, 2007).  The predicted stoichiometry of ion flux 




: substrate ratio 
is 1:1:2 for DAT and 1:1:1 for NET and the 5-HT transporter SERT.  In SERT, one K
+
 ion is 
also transported out of the cell (Gu et al., 1994; Rudnick, 1998). Substrate-induced current 
measurements obtained from the transporters have been significantly greater than expected for a 
fixed stoichiometry (Sonders et al., 1997).  Previous work has shown that substrate induced 
currents have a better correlation with the ability of the substrate to stimulate reverse transport 
(efflux) rather than uptake (influx) (Sitte et al., 1998). 
Measurements of transporter currents 
Two-electrode voltage clamping (TEVC) is commonly used to measure currents.  This powerful 
technique allows the simultaneous control of membrane voltage and measurement of current to 
determine charge exchange.  TEVC is widely used to measure large currents from ion channels.  
The technique can be applied to measure much smaller currents from transporter expressing 
systems due to their similarity to ligand-gated channels (Sonders and Amara, 1996).  A voltage-
recording electrode placed inside the cell measures the membrane potential.  The recorded 
membrane voltage is compared to the command (or clamped) voltage set by the experimenter.  




neurons.  The clamp circuitry passes a current back into the cell through the second, current 
electrode to hold the membrane potential at the desired level.  The counter current applied to the 
cell is measured and represents the amount of actual current or charge flowing across the cell 
membrane.  As is the case during transport, when the inside of the cell becomes positive, a 
negative countercurrent is applied by the current electrode.  This produces a downward 
deflecting, inward current (Sonders et al., 1997).  Useful information is gained from current-
voltage relationships (I-V curves), which are current measurements plotted over a range of 
applied voltages and usually have control currents subtracted from transporter-mediated currents.  
The direction of the current trace gives an indication of the net charge of ions across the 
membrane.  The point at which the curve crosses the x-axis is the reversal potential, where there 
is no net ion flow.  Conditions (e.g. drug treatments, mutant protein expression) that alter 
features of the current can serve as an indication to changes in composition of ions
 
contributing 
to the current.  Substrates, inhibitors and ion substitutions can be utilized to understand ligand 






) necessary to 





Types of transporter-mediated currents 
Three types of transporter-mediated currents have been identified: substrate independent leak 
current, coupled substrate-induced current, and uncoupled substrate-induced current.  
Measurable current is obtained in the absence of substrate that can be blocked by classic 
transporter inhibitors like cocaine and by substrates like DA, as well (Sonders et al., 1997).  The 
conductance that arises from this leakiness within transporters in the absence of substrate has 
been termed the leak current.  The relevance of this leak conductance is not well known, but has 
been implicated in maintenance of cell membrane potential and neuronal excitability (Sonders 
and Amara, 1996).   
Substrate-induced inward currents that are coupled to transport have been demonstrated in 
neuronal cultures, cells, and oocytes systems expressing transporters, where application of 
endogenous (5-HT, NE, DA) substrates or AMPH stimulates inward currents that rapidly return 
to baseline and persist depending on the length of substrate application.  Substrate-induced 
inward currents are also voltage dependent, as demonstrated by the declining magnitude of 
AMPH inward currents (Erreger et al., 2008) and a reduction in the transporter:flux ratio (DA: 
ion) with increased membrane depolarization (more positive potential) (Sonders and Amara, 
1996).  These inward currents are transporter specific as they are not observed in control cells 
that do not express the transporter.  When measured with high temporal resolution, the substrate-
induced inward current has two distinguishable components with different characteristics 




decays followed by a slow steady-state current that persists until the substrate is removed.  Both 
currents are substrate dependent, though the steady-state current saturates at a much lower 
AMPH concentrations.  AMPH stimulates a larger peak current than DA when the same 
concentrations are used; showing a unique capability of AMPH to stimulate more charge transfer 
across the membrane than DA (Erreger et al., 2008).  Sodium also has varying effects on the 
currents, where the Na
+
 gradient is required for the steady-state current but not the peak current, 
which is dependent on extracellular Na
+
 (Erreger et al., 2008).  
Significant components of substrate-induced currents are uncoupled from transport since the 
currents generated are far greater than the predicted stoichiometry for transport (Sonders et al., 
1997).  This added to the notion of monoamine transporters possessing channel-like properties 
(Carvelli et al., 2004; Kahlig et al., 2005).  Kahlig and colleagues provided evidence of AMPH 
stimulating single-channel currents in cells expressing DAT or in dopaminergic neurons (Kahlig 
et al., 2005).  Inhibitor-sensitive, single channel events were observed in DAT-1 DA neurons of 
Caenorhabditis elegans that contributed to membrane depolarization (Carvelli et al., 2004).  The 
recordings of DAT channel-like activity show rapid bursts of DA efflux that would be similar to 
the amount of DA released from a synaptic vesicle.  These channel events are absent without 




.  This 
channel-like activity in Caenorhabditis elegans is DAT-mediated as it is not detected without 
DAT present and still occurs when DA receptors are pharmacologically inhibited (DeFelice and 
Goswami, 2007).  Based upon the gating mechanism proposed from the LeuT crystallization and 




achieved through simultaneous opening of the extra-and intracellular gates.  The ‘pore’ created 
would allow more movement of charges through the transporter.  It is not exactly clear what 
determines the probability of a transporter assuming a channel like mode.  Recently, another 
hypothesis has surfaced to explain DAT currents elicited by AMPH.  According to the molecular 
stent hypothesis, after transport, AMPH can bind internally and act as a “molecular stent that 
holds the transporter open” even after AMPH removal (Rodriguez-Menchaca et al., 2012).  
Though many important strides have been made, elucidating the mechanism of AMPH action 
and DAT reversal remains a continued area of investigation. 
Transport measurement with the fluorescent substrate ASP
+
  
Classic radioligand assays that measure binding and transport have been utilized to establish 
important transporter properties, like substrate and inhibitor affinity constants.  Radioligand 
assays are beneficial due to their high sensitivity, availability of compounds and rapid detection 
methods.  However, a major disadvantage of radioligand assays is their inability to measure real-
time changes of transporter functions.  Techniques like rotating disk voltammetry provide 
alternate methods with improved spatial resolution for measuring transport activities (Povlock 
and Schenk, 1997).  A relatively new method utilized bySchwartz et al. (2003) demonstrated that 
ASP
+
 ((4-4-dimethylamino)-styrl)-N-methylpyridinium) is a viable fluorescent substrate for 
hNET and hDAT.  ASP
+
 is a fluorescent analog of the neurotoxin MPP
+
 (Figure 1-6), which is 
cleaved from of MPTP. ASP
+
 has several similarities to native and previously identified 
substrates.  ASP
+
 competes for DA and NE uptake with micromolar potencies in hDAT- and 








and sensitive to temperature and competitive pharmacological inhibition with cocaine (DAT and 
NET blocker), depsiramine (specific NET blocker), or high substrate concentrations (Schwartz et 
al., 2003). 
 
 Figure 1-6. Chemical structures of ASP
+
 (left) and MPP
+
 (right) (Mason et al., 2005).  
 
Transporter-mediated uptake of ASP
+
 has been measured in heterologous cell expression 
systems and native neuronal cultures (Schwartz et al., 2003).  ASP
+
 is an inexpensive compound 
that can distinguish between substrate binding at the membrane and transport within a single cell 






 uptake activity has been well characterized and described as having two phases that are 
visualized by plotting the fluorescent intensity of the whole cell over a given time period after 
ASP
+
 application (Schwartz et al., 2003).  Phase I is the rapid binding phase; and Phase II is the 
slower transport phase.  Native substrates, like NE, are also able to reduce ASP
+
 fluorescence 
due to competition of the two substrates for transporter binding.  ASP
+
 accumulation is detected 
in parental HEK293 cell lines, although the response in cells expressing transporter is 
significantly greater (Schwartz et al., 2003).  The non-specific accumulation may be attributed to 
uptake through the low affinity, high capacity organic cation transporters (OCT) that can be 
expressed in HEK cells.  Inhibitors, such as decynium 22, exists that specifically block OCTs, 
but have not been directly used to inhibit ASP
+
 accumulation.  Due to mitochondrial 
sequestration ASP
+
 is not subject to efflux (Schwartz et al., 2003), and thus provides the unique 
experimental advantage of evaluating only the influx of substrate without the component of 
efflux.  
Thesis Summary 
Uncovering the mechanistic details governing transporter movements is a premier research focus 
for many laboratories.  This project was initiated to understand the role of the N-terminal Thr 
residue within the conserved RETW sequence in the regulation of DAT and NET functions.  
Initial interests were in identifying additional phosphorylation sites involved in regulating 
reverse transport.  To this end, the Thr residue of the highly conserved RETW sequence in hDAT 
and hNET was mutated to alanine (TA, Ala, A) or aspartic acid (TD, Asp, D) to mimic a 




were stably expressed in human embryonic kidney (HEK) cells.  The Thr 62 mutations of hDAT 
and hNET altered the dynamics of the transporter conformation in a way that profoundly 
impacted its function.  The T62D-hDAT mutation showed reduced Km and Vmax for [
3
H]DA 
uptake and abrogated amphetamine (AMPH)-stimulated DA efflux, but had elevated basal DA 
efflux as compared to WT- and T62A-hDAT.  These aberrant functions of the T62D mutant were 
partially suppressed when measured in the presence of zinc.  It was concluded that T62D-hDAT 
is predominately inward facing, while T62A-hDAT functions more like WT-hDAT in the 
outward conformation (Guptaroy et al., 2009). 
The work within this dissertation extends the characterization of the Thr mutations and 
functional properties of the transporter.  As detailed in Chapter 2, the effects of the 
corresponding Thr mutations in hNET (T58A and T58D) on transporter surface expression, 
uptake of DA, and basal and AMPH-induced DA efflux were evaluated.  The effects of the T58D 
mutation on these properties of hNET were similar to previous findings in the T62D hDAT 
mutant.  The greater portion of Chapter 2 provides an extensive analysis of alterations to 
substrate and inhibitor interactions with the Thr mutant hDATs and hNETs.  An array of 
radioligand uptake and inhibitor binding competition assays revealed an enhanced sensitivity to 
all substrates tested in both hDAT and hNET TD mutants.  The actions of inhibitors differed in 
that their activity was not affected by the Thr mutations in hNET; however, changes were 
observed in T62D hDAT expressing cells that were dependent on the inhibitor structure 
(Guptaroy et al., 2011).  These data emphasized the strong and differential influence transporter 




Chapter 3 further probes the elevation of constitutive DA efflux seen in the T62D mutation of 
hDAT.  We theorized that the inward facing conformation caused by the TD mutation was a 
representation of WT hDAT in an efflux-willing orientation elicited by, for instance, exposure to 
AMPH.  Three hypotheses were tested to support this theory and explain the increase in basal 
DA efflux in T62D-hDAT.  They were: 1) a loss of intracellular substrate retention 2) an 
intrinsic membrane depolarization induced by the mutation; and 3) an enhanced dependence on 
intracellular sodium.  My approach to these hypotheses combined various techniques: confocal 
microscopy with the fluorescent substrate ASP
+
, electrophysiology measurements in Xenopus 
oocytes, and radioligand assays under sodium replacement conditions.  My results have led me to 
conclude that the T62D mutation in hDAT produces a sodium-primed transporter orientation that 
favors reverse transport.  Surprisingly, the T62D-hDAT exhibited independence of sodium for 
DA efflux, not DA influx.  These data strongly support the concept of T62D-hDAT mutant as an 
hDAT efflux model, but also the notion of separate regulation of uptake and efflux through 
DAT.    
The final chapter provides conclusions and implications for the Thr DAT and NET mutants.  A 
molecular interaction of T62 and Y335 has been implicated in formation of the inward facing 
transporter (Shan et al., 2011) that, along other molecular interactions, is disrupted by the T62D 
mutation (Guptaroy et al., 2009).  Preliminary experiments measured the uptake and efflux 
properties in an hDAT cell line where the Y335 residue was mutated to a phenylalanine (Y335F) 
and compared to WT and Thr62 hDAT mutants.  This work will demonstrate the ability of a 




include the impact of the Thr mutations on transporter trafficking and regulation by second 
messenger systems, like PKC signaling; interactions with additional proteins such as the D2 DA 
autoreceptor and syntaxin 1A; and the potential application of the T62D-hDAT mutant mouse as 
a model for diseases involving excessive extracellular DA.  
Taken together the data and conclusions from this dissertation add to our understanding of how 
monoamine transporters operate and potential changes that may occur when exposed to drugs 
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The human dopamine and norepinephrine transporters (hDAT and hNET, respectively) control 
neurotransmitter levels within the synaptic cleft and are the site of action for amphetamine 
(AMPH) and cocaine.  We investigated the role of a threonine residue within the highly 
conserved and putative phosphorylation sequence RETW, located just before transmembrane 
domain 1, in regulating hNET and hDAT function.  The Thr residue was mutated to either 
alanine or aspartate.  Similar to the inward facing T62D-hDAT, T58D-hNET demonstrated 
reduced [
3
H]DA uptake but enhanced basal DA efflux as compared to hNET with no further 
effect of AMPH.  The mutations had profound effects on substrate function and binding.  The 
potency of substrates to inhibit [
3
H]DA uptake and compete with radioligand binding was 
increased in T→A and/or T→D mutants.  Substrates, but not inhibitors, demonstrated 
temperature-sensitive effects of binding.  Neither the functional potency nor binding affinity for 
hNET blockers was altered from wild type in hNET mutants. There was, however, a significant 
reduction in potency for cocaine and benztropine to inhibit [
3
H]DA uptake in T62D-hDAT as 
compared with hDAT.  The potency of these drugs to inhibit [
3
H](-)-2-β-carbomethoxy-3-β-(4-
fluorophenyl)tropane-1,5-napthalenedisulfonate (WIN 35,428) binding was not increased, 
demonstrating a discordance between functional and binding site effects.  Taken together, these 
results concur with the notion that the T→D mutation in RETW alters the preferred 
conformation of both hNET and hDAT to favor one that is more inward facing.  Although 
substrate activity and binding are primarily altered in this conformation, the function of 





The availability of the monoamine neurotransmitters dopamine (DA) and norepinephrine (NE) 
around the synaptic cleft is regulated by DA and NE transporters (DAT and NET, respectively), 
which mediate the reuptake of released neurotransmitter into the presynaptic terminal (Amara 
and Kuhar, 1993; Blakely and Bauman, 2000; Giros and Caron, 1993). Transporter-mediated 
reuptake terminates the presence of neurotransmitter at the synaptic cleft. 




 dependent transporter family (Torres et 





 ions (Chen and Reith, 2000; Norregaard and Gether, 2001).  An alternating access 
model was proposed to explain the functioning of these transporters, in which the transporter 
would oscillate between two primary conformations, an “outward-facing” mode accessible to the 
extracellular medium and an “inward-facing” mode that is open to the intracellular milieu 
(Rudnick, 1997).  According to this model, both substrate and inhibitors bind the transporter 
when it assumes an outward-facing conformation.  Substrates, however, elicit a conformational 






Monoamine transporters contain 12 transmembrane domains (TM), connecting intracellular and 
extracellular loops and intracellular amino and carboxyl termini (Torres et al., 2003).  The 
elucidation of the crystal structure of the bacterial leucine transporter (LeuTAa), a homolog of 




transporters (Yamashita et al., 2005).  The structure revealed a substrate-occluded state possibly 
representing a state between the outward- and inward-facing conformations and suggested the 
existence of important ionic interactions amongst residues in the N-terminus (Arg5), TM8 
(Asp369) and TM6 (Tyr206) as part of a network of ionic interactions that could constitute an 
intracellular “gate” (Singh, 2008; Yamashita et al., 2005).  Mutagenesis studies demonstrate 
similar interactions between corresponding residues in DAT (Arg60 in the N terminus, Asp436 
at the end of TM8 and Tyr335 in intracellular loop 3 close to TM6) (Kniazeff et al., 2008).  
These studies establish that the N-terminal Arg60 (DAT) residue, which is highly conserved in 
monoamine transporters, plays a critical role in transporter function.  Mutations of Tyr335 and 
Asp436 also have profound impact on DAT conformation and function; specifically, mutation of 
all of these residues (Arg60, Asp436, and Tyr335) of DAT to Ala appear to promote a 
conformation (presumably inward-facing) of the transporter in which DA uptake is significantly 
compromised (Kniazeff et al., 2008; Loland et al., 2004; Loland et al., 2002).  
 The RETW motif is conserved in all monoamine transporters (residues 60-63 in DAT and 56-59 
in NET), and mutations within this motif have robust effects on hDAT function.  Mutation of 
both Arg and Trp, but not Glu, within this motif in hDAT profoundly affects DA uptake (Chen et 
al., 2001; Kniazeff et al., 2008). In the corresponding sequence (RDTW) in GAT-1, deletion of 
either Arg44, Thr46, or Trp47 render the transporter totally inactive (Bennett et al., 2000), and 
only certain substitutions are tolerated.  We have demonstrated that mutation of the Thr residue 
within the RETW motif similarly has profound effect on DAT conformation and function 




inward-facing conformation, which promotes constitutive efflux of DA from cells and prevents 
accumulation of internal DA.  We now present evidence for a similar, although not identical, 
effect of the same mutations in the corresponding Thr residue (Thr58) in hNET.  These studies 
further establish the importance of the highly conserved N-terminal residues proximal to TM1 in 
maintaining monoamine transporter conformations that sustain normal transporter function. 
Monoamine transporters are also the target for both therapeutic and abused drugs such as 
antidepressants, AMPH, and cocaine (Norregaard and Gether, 2001).  Mutants of DAT with 
altered conformational equilibrium are useful tools in binding studies and provide invaluable 
information about the affinity of structurally diverse transporter inhibitors (Liang et al., 2009; 
Schmitt et al., 2008).  These studies demonstrate that the transporter and ligand conformation 
determines the interaction between them.  In the present study, we used the N-terminal threonine 
mutants of hDAT (Thr62) and hNET (Thr58) to investigate the effect of various substrates and 
inhibitors on transport and binding characteristics.  We find that in Thr to Asp mutants, which 
favor an inward-facing conformation, the affinity for both catechol and non-catechol substrates is 
enhanced and that substrate binding is temperature-dependent.  Conversely, these mutations have 
no appreciable effect on the interaction of the transporters with most inhibitors, with the 
exception of benztropine and cocaine in hDAT.  
Materials and Methods 
Mutagenesis and Generation of Stable Cell Lines. The hDAT mutants and cell lines were 




polymerase chain reaction using sense and antisense oligonucleotides and pfu polymerase 
(Stratagene, La Jolla, CA).  After digestion of parental DNA with Dpn I (Promega Corporation, 
Madison, WI), competent DH5α cells were transformed with mutagenic DNA.  Mutations were 
confirmed by DNA sequencing and the cDNAs were used to transfect human embryonic kidney 
293 cells using Lipofectamine (Invitrogen, Carlsbad, CA).  A stable pool of G418-resistant cells 
was selected and maintained in the presence of 100 µg/ml G418 in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin at 37°C and 5% 
CO2. 
Surface Biotinylation and Immunoblotting. To label cell surface transporters, cells were 
treated with sulfosuccinimidyl-2-(biotinamido) ethyl-1, 3-dithiopropionate (sulfo-NHS-SS 
biotin) (Pierce, Rockford, IL) at 4°C as described previously (Johnson et al., 2005).  The reaction 
was quenched for 15 min with 100 mM glycine at 4°C.  Cells were lysed in solubilization buffer 
(25 mM Tris, 150 mM NaCl, 1 mM EDTA, 5 mM N-ethylmalemeide, 100 µM 
phenylmethylsulfonyl fluoride, and 1% Triton X-100) containing protease inhibitors (Roche, 
Indianapolis, IN) and centrifuged at 20,000g to remove cell debris.  Biotinylated proteins in cell 
lysates containing 800 µg of protein were bound to 50 µl streptavidin beads (Pierce) by 
incubating for 1 hr at room temperature.  The beads were washed with solubilization buffer and 
eluted in 25 µl SDS-polyacrylamide gel electrophoresis sample buffer containing 100 mM 
dithiothreitol and resolved by electrophoresis on a 10% Tris-glycine gel along with samples of 
the lysate.  Proteins were transferred to a nitrocellulose membrane (GE Healthcare Chalfont St. 




NaCl, and 0.1% Tween 20.  hNET was detected using anti-NET (Alpha Diagnositcs, San 
Antonio, TX) and horse radish peroxidase-conjugated secondary antibody (Santa Cruz 
Biotechnologies Inc, Santa Cruz, CA) by enhanced chemiluminiscence reagent (Pierce).  
Quantification of bands was done by densitometry using Scion Image software (Scion 
Corporation, Frederick, MD). 
[
3
H]DA Uptake and Competition Assays. Cells were plated on 24-well plates at a density of 
100,000 cells per well one day prior to performing the assays.  [
3
H]DA uptake was measured in 
KRH (25 mM HEPES, pH 7.4, 125 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 
1.2 mM MgSO4, and 5.6 mM glucose containing 50 µM pargyline, 1 mM tropolone and 50 µM 
ascorbic acid) in the absence or presence of 10 µM GBR12935 (Sigma, St. Louis, MO) or 100 
µM cocaine.  The initial rate of uptake was analyzed using 30 nM to 3 µM [
3
H]DA (specific 
activity 59.3 Ci/mmol; PerkinElmer Life and Analytical Sciences, Waltham, MA) for 2 min at 
room temperature in a final volume of 250 µl.  The reaction was stopped by rapidly washing 
three times with 1 ml of ice cold phosphate-buffered saline.  Cells were solubilized in 1% SDS 
and radioactivity was measured using Scintverse (Thermo Fisher Scientific, Waltham, MA) in a 
liquid scintillation counter (LS 5801; Beckman Coulter, Fullerton, CA).  For competition assays, 
cells were incubated with [
3
H]DA for 3 min in the presence of increasing concentrations of 
competing substrates or inhibitors (Sigma-Aldrich).  Cells were preincubated with inhibitors for 
10 min before initiating [
3
H]DA uptake and substrates were added simultaneously with [
3
H]DA. 
Non-specific binding was determined in the presence of transporter inhibitors (DAT, 5-10 µM 




for uptake inhibition by substrates will represent the Km for the substrate.  In case of inhibitors, 
the IC50 values are close to the Ki values, because 30 nM [
3
H]DA is far below the Km for DA.  
[
3
H]DA Efflux. Basal efflux of [
3
H]DA was measured in cells plated on 12 well plates at a 
density of 1.5*10
5
 cells per well.  Cells were loaded for 20 min at room temperature with 1 µM 
[
3
H]DA in KRH.  After loading, cells were washed rapidly with KRH three times.  KRH (500 µl) 
was added and removed after 5 min for scintillation counting and this was repeated at 10- and 
15-min time points.  After 15 min, cells were lysed in 1% SDS and counted to determine the 
amount of [
3
H]DA remaining in the cells.  Cells from a separate well were lysed immediately 
after loading with [
3
H]DA to obtain an estimate of the total amount of [
3
H]DA in the cells at the 
start of the experiment. 
AMPH-stimulated DA Efflux. Confluent 100 mm plates of cells were washed twice with KRH 
and incubated at 37
o
C with 15 µM DA for 30 min.  Cells were washed with KRH, harvested, and 
resuspended in 200 µl KRH and 150 µl of the cells were placed on a Whatman GF/B filter 
(Whatman, Clifton, NJ) in a chamber of a Brandel superfusion apparatus (SF-12; Brandel, 
Gaithersburg, MD).  Superfusion chambers were maintained at room temperature and KRH was 
perfused at a rate of 400 µl/min.  Samples were collected every 2 min.  Following a 45 min wash 
to reduce baseline, cells received a 2-min bolus of 10 µM d-AMPH.  Fractions were collected for 
the next 50 min.  Samples were collected into vials containing 25 µl of an internal standard 
solution (0.05 M HClO4, 4.55 mM dihydrobenzylamine, 1M metabisulfate and 0.1 M EDTA) as 
described previously (Kantor et al., 2001). Samples were stored at –80
o




measured by high pressure liquid chromatography with electrochemical detection.  DA efflux 
was quantified as the peak DA in the eluent.  
Binding Assays. Cells were plated on 24-well plates at a density of 10
5
 cells per well one day 
before the experiment.  Cells were rinsed with KRH and binding of 4 nM [
3
H](-)-2-β-
carbomethoxy-3-β-(4-fluorophenyl)tropane-1,5-napthalenedisulfonate (WIN 35,428) (specific 
activity, 85 Ci/mmol; Life and Analytical Sciences) (hDAT) or  3 nM [
3
H]nisoxetine ( specific 
activity 87.2 Ci/mmol; Perkin Elmer, Life and Analytical Sciences) (hNET) was measured in the 
absence or presence of transporter inhibitors (DAT: 5-10µM GBR-12935 or 100µM cocaine; 
NET: 1-3 µM desipramine or 100 µM cocaine).  All assays were performed at the peak time for 
saturation binding determined previously (30 min for [
3
H]WIN 35,428 and 90 min for 
[
3
H]nisoxetine).  Reactions were incubated for 30 min or 90 min at room temperature or on ice as 
indicated.  Binding was attenuated by rapidly washing three times with ice-cold phosphate-
buffered saline.  Cells were solubilized in 1% SDS and counted in a Beckman scintillation 
counter using Scintverse.  In competition assays, the indicated concentrations of substrates or 
inhibitors were used during incubations.  For Kd determination, cells were incubated with 
increasing concentrations of [
3
H]WIN 35,428 (1-100 nM) for hDAT and [
3
H]nisoxetine (1-30 
nM) for hNET and processed as described above.  Ki values reported in the legends of Tables 2-3 
and 2-4 were determined from the Cheng-Prusoff correction in GraphPad Prism using the IC50 




Statistical Analysis. Kinetic constants, including Km, Vmax and IC50 values for the transporter 
constructs were determined by nonlinear regression analysis of the mean values for each mutant 
using GraphPad Prism version 5 (GraphPad Software, San Diego, CA).  Statistical significance 
was determined using GraphPad Prism version 5 either by comparison to wild type using a 2-
way ANOVA with posttest Bonferroni analysis or with an F-test by comparing fits in which 
selected values were constrained to be equal or were allowed to differ.  The null hypothesis was 
that the best fit parameter for the value did not differ.  A conclusion of statistical significance 
represents a rejection of the null hypothesis and indicates a difference between designated 
values.  Values plus the 95% confidence levels are reported.  In most cases, the F-distributions 
are reported in the tables and figure legends to maintain flow in the text.  
Results  
Surface Expression and DA Uptake in hNET and Mutant Transporters. Both T58A-hNET 
and T58D-hNET express in the cell at levels equivalent to hNET, but traffic less efficiently to 
the cell surface as compared to hNET.  As shown in Figure 2-1A, total transporter levels in the 
lysate on a protein basis were the same for all three transporters but the amount of surface 
transporter was reduced in T58A-hNET and T58D-hNET (Figure 2-1A).  A quantitative 
representation of the amount of surface transporter as fold of hNET demonstrated that T58A-
hNET is expressed on the surface at 60% and T58D-hDAT at 50% of the level of hNET (Figure 




Inward transport through the hNET mutants was determined by measuring [
3
H]DA uptake.  
Using [
3
H]DA is valid because the NET can transport both NE and DA. In fact, NET has greater 
affinity for DA than NE and greater Vmax values for DA uptake as compared to NE (Eshleman et 
al., 1999; Gu et al., 1994). In view of this preference of NET for DA we used [
3
H]DA transport 
to understand the properties of substrate transport in the hNET constructs. Other mutants of NET 




H]DA uptake velocities for the hNET constructs were determined from the initial rates 
calculated from time course curves at varying concentrations of [
3
H]DA.  Values were 
normalized to surface expression of hNET.  The data in Figure 2-1C show that T58D-hNET cells 
had a dramatically reduced Vmax as compared with hNET (p < 0.05). There was a similar 
significant reduction of the Vmax for [
3
H]DA uptake in T62D-hDAT as compared to hDAT 
(Table 2-1) (Guptaroy et al., 2009).  On the contrary, there was a significant increase in the 
normalized (corrected for surface expression) Vmax value for [
3
H]DA uptake in T58A-hNET (1.3 
pmol per10
5
 cells per min) as compared to hNET (0.76  pmol per 10
5
 cells per min, p < 0.0003). 
This is in contrast to the corresponding hDAT mutant T62A-hDAT (Guptaroy et al., 2009), in 
which the Vmax value was significantly lower than that of hDAT (Table 2-1).  In hNET, 
therefore, the mutation of Thr58 to Ala or to Asp has opposing effects on [
3
H]DA uptake.  These 
results demonstrate that although the Asp mutation of the corresponding threonine residues in 
hDAT and hNET similarly affects DA uptake, the Ala mutation has a differential effect on 
[
3






H]DA uptake  amongst hNET, T58A-hNET and T58D-hNET (Table 2-1).  In 
keeping with previous reports (Gu et al., 1994) we also observe a greater affinity for [
3
H]DA in 
hNET (Km, 0.23 µM) compared to hDAT (Km, 2.2  µM) (p < 0.002).  The difference between Km 
values for [
3
H]DA uptake between T62A-hDAT and T58A-hNET or between T62D-hDAT and 
T58D-hNET were reduced or negated, demonstrating that mutation of the threonine counteracted 
structural differences between hDAT and hNET in affinity for [
3
H]DA.  The Vmax for T58A-
hNET, however, was more than 3 times that for T62A-hDAT (p < 0.0001). 
 
 Figure 2-1. Surface expression and [
3
H]DA uptake in hNET and hNET-T58 mutants. Cell surface 
 expression of hNET, T58A-hNET, or T58D-hNET was analyzed by biotinylation as described under 
 Materials and Methods. A representative Western blot (A) and quantitation of surface transporter compared 
 with hNET (B) are shown. Data represent mean ± S.E.M, n = 7. C, [
3
H]DA uptake (n = 3) was calculated in 
 hNET (■), T58A-hNET (▲),and T58D-hNET (◊) by measuring initial rates at increasing concentrations of 
 [
3





 Table 2-1. Kinetic properties of [
3
H]DA uptake in hNET, hDAT, and threonine mutants Km and Vmax 
 values were determined by nonlinear regression using Prism. 
 The Vmax values from this analysis were normalized to wild-type surface expression and are shown as mean 
 ±S.E.M. Statistical significance was determined using Prism F test by comparing fits in which selected 
 values were constrained to be equal or were allowed to differ. The null hypothesis was that the best-fit 
 parameter for the value did not differ. A conclusion of statistical significance represents a rejection of the 
 null hypothesis and indicates a difference between designated values. Comparison of Vmax values within 
 hNET: hNET vs. T58A-hNET, P < 0.001, F1,26 = 17.21; hNET vs. T58D-hNET, P < 0.05, F1,26 = 5.347.  
 Comparison of Vmax values within hDAT: hDAT vs. T62A-hDAT, P < 0.01, F1,57 = 7.097; hDAT vs. 
 T62D-hDAT, P < 0.05, F1,64 = 4.920. 
 
Basal Efflux Is Elevated in the T58D-hNET Mutant. Because the transporter basically 
functions as a pump in forward and reverse transport modes, a reduction in substrate uptake (as 
seen in T58D-hNET) could be due to an increase in DA efflux.  In order to evaluate this 
possibility for the T58D-hNET mutant, cells were loaded with [
3
H]DA for 20 min at room 
temperature and rapidly washed.  Efflux of [
3
H]DA was measured every 5 min for 15 min as 
described under Materials and Methods. In Figure 2-2A, basal efflux of [
3
H]DA is expressed as 
percentage of the total amount of [
3
H]DA present in the cells after the 20 min DA loading period. 
This representation of the data is independent of the variable surface expression because both the 




DA content in the cells after the loading period in units of counts per minute per 10
5
 cells was: 
21,649 ± 809 for hNET, 19,062 ± 486 for T58A-hNET and 6,364 ± 726 for T58A-hDAT (n = 3).  
The basal efflux of [
3
H]DA in the 5-min fraction in T58D-hNET was significantly greater than in 
either hNET or T58A-hNET cells (two-way ANOVA, p < 0.001). This efflux reached a level 
comparable to hNET and T58A-hNET by 10 min.  These results suggest that the greatly reduced 
Vmax of DA uptake in T58D-hNET cells is due to an increase in basal DA efflux that prevents the 
accumulation of intracellular DA, similar to our results reported with T62D-hDAT (Guptaroy et 
al., 2009). For T62D-hDAT this property was attributed to a preference for a more inward-facing 
conformation. In view of the similarity in characteristics of [
3
H]DA uptake and basal [
3
H]DA 
efflux between T62D-hDAT and T58D-hNET, it is reasonable to postulate that the underlying 
mechanism leading to this phenotype is the same in both these mutant transporters, supporting 
the conclusion that T58D-hNET, like T62D-hDAT, is predominantly inward-facing.  
AMPH-Stimulated DA Efflux Is Reduced in T58A-hNET. AMPH-stimulated DA efflux was 
measured in T58A-hNET and hNET at a single AMPH concentration (10 µM) using a 
superfusion protocol.  Following loading with unlabeled DA, cells were placed in a superfusion 
apparatus, and DA efflux in response to 10 µM AMPH was measured.  To eliminate variability 
due to uneven loading, data were calculated as fractional DA efflux, which is the amount of DA 
in the effluent as a percentage of the total amount of DA originally present in the cells. As shown 
in Figure 2-2B, in T58A-hNET cells there was significantly less AMPH-stimulated DA efflux as 
compared to hNET.  The fact that DA influx was enhanced but the responsiveness to AMPH was 




conformation that is slow to transition back to outward-facing.  On the contrary, the T58D-hNET 
mutant was completely unresponsive to AMPH (data not shown).  As demonstrated in the data in 
Figure 2-2A, the baseline efflux was elevated in T58D-hNET compared with hNET and T58A-
hNET, but there was no response to AMPH. 
 
 Figure 2-2. Functional DA efflux properties of hNET mutants. A, cells were loaded with 5 µM [3H]DA 
 for 20 min at room temperature and washed with KRH. Basal efflux was measured in hNET (■), T58A-
 hNET (▲), and T58D-hNET (◊) as described under Materials and Methods. Efflux is expressed as the 
 percentage of total [
3
H]DA present in the cell at the start of the experiment (n = 3). In a two-way ANOVA 
 considering time and mutants, p < 0.001 for time, p < 0.01 for mutants, and p < 0.001 for interaction 
 between time and mutants. In Bonferroni post-test, ***, p < 0.001 for hNET or T58A-hNET compared with 
 T58D-hNET. B, AMPH-stimulated DA efflux was assessed by superfusion of the cells as described under 
 Materials and Methods. Cells were loaded with DA, washed with KRH for 30 min, and then challenged 
 with AMPH for 2 min. Fractions (800 µl) were collected, and DA content was analyzed by high-
 performance liquid chromatography and electrochemical detection. Data are expressed as DA concentration 
 in each fraction as a percentage of total amount of DA taken up in the cells (n = 4). In a two-way ANOVA 
 comparing time with mutants, p < 0.0001 for time, p < 0.01 for mutants, and p < 0.001 for interaction 
 between time and mutants. In Bonferroni post-test, ***, p < 0.001; **, p < 0.01. 
The IC50 for Inhibition of [
3
H]DA uptake by Substrates Is Decreased in Thr mutants. 
Mutants with altered conformational equilibrium interact differentially with substrates and 




al., 2002; Schmitt et al., 2008).  We examined the effect of the mutations on the potency for 
substrates and inhibitors to functionally inhibit [
3
H]DA uptake.  As shown in Figure 2-3, 
mutation of Thr-58 in hNET to Asp increases the affinity for both catechol (Figure 2-3A, DA, 
and Figure 2-3B, NE) and non-catechol substrates (Figure 2-3C, AMPH), as demonstrated by a 
leftward shift of the competition curve.  Accordingly, the IC50 values were significantly lower for 
DA, NE, and AMPH in T58D-hNET as compared to hNET.  The IC50 values, 95% confidence 
intervals (CI), and F-distribution showing significant differences are given in Table 2-2. 
Mutation of Thr58 to Ala in hNET similarly increased the potency of DA and AMPH in 
inhibiting [
3
H]DA uptake but not to the same extent as for the T→D mutation (T58A-hNET 
versus T58D-hNET for DA, p < 0.0001; for AMPH, p < 0.0001).  A similar increase in affinity 
for all three substrates was observed in T62D-hDAT (Figure 2-3C & D and Table 2-2) compared 
with hDAT.  As with Thr58 in hNET, mutation of Thr62 in hDAT to Ala increased the potency 
for DA and AMPH but not to same degree as the T→D mutation (T62A-hDAT versus T62D-
hDAT for DA, p < 0.05; for AMPH, p < 0.0001).  Furthermore, the preference for AMPH over 
DA is lost in the T58D-hNET mutants and greatly reduced in the T62D-hDAT mutants as 
compared with wild type.  The potency of NE, however, was not significantly changed by a Thr-
to-Ala mutation in either hNET or hDAT. 
In contrast to the change in IC50 values for DA uptake, the mutations have no effect on the 
sensitivity of inhibitors to block [
3
H]DA transport in hNET mutants.  IC50 values for cocaine, 
benztropine, nisoxetine, and desipramine did not significantly differ amongst hNET, T58A-






H]DA uptake was reduced in T62D-hDAT compared with hDAT.  Both drugs are more 
selective for hDAT than for hNET.  The potencies of cocaine and benztropine were reduced in 
T62D-hDAT as compared with wild type, but they were able to completely block the [
3
H]DA 
uptake.  The potency of GBR12935, a highly selective DAT inhibitor of a different structural 
class, was unaltered by mutation of Thr62 to Asp.  A Thr to Ala mutation did not change potency 
for any inhibitor in either hNET or hDAT.  Therefore, mutation of Thr to Asp or Thr to Ala 
within the RETW sequence of hDAT or hNET disrupted the functional activity of the transporter 
substrates much more than the transporter inhibitors. 
The IC50 values of the inhibitors for hNET reported here are higher than some reported values 
(Eshleman et al., 1999; Han and Gu, 2006; Owens et al., 1997) but similar to others (Mortensen 
and Amara, 2006).  This could be attributed to differences in assay conditions and cell lines (Han 
and Gu, 2006).  Passage number and expression level in transfected cells caused variability in the 
inhibition potency of cocaine for DA uptake (Chen and Reith, 2007; Ukairo et al., 2007).  The 
use of [
3
H]DA as opposed to [
3
H]NE as substrate might have affected the IC50 values.  In 
contrast, the IC50 for inhibition of binding (Table 2-3, Table 2-4) were comparable with values 
reported previously (Reith et al., 2005), possibly because of the similarity of the assay condition 





 Figure 2-3. Mutation of Thr58 (hNET) and Thr62 (hDAT) to aspartate results in enhanced substrate 
 potency. DA transport was measured in hNET (■), T58A-hNET (▲), and T58D-hNET (◊) cells in the 
 presence of increasing concentration of DA (A), NE (B), and AMPH (C) and in hDAT (■), T62A-hDAT 
 (▲), and T62D-hDAT (◊) cells in the presence of increasing concentrations of DA (D) and NE (E). Cells 
 were incubated with 30 nM [
3
H]DA and indicated concentrations of competing substrate for 3 min at room 
 temperature and processed as described under Materials and Methods. Data are expressed as percentage of 
 [
3
H]DA uptake in the absence of any added substrate (control). IC50 values, 95% confidence intervals, and 





 Table 2-2. Potency for substrates and inhibitors in inhibiting [
3
H]DA uptake in hNET and hDAT 
 mutants. 
 Data were calculated as a percentage of uptake in the absence of competing substrate or inhibitor and 
 analyzed by nonlinear regression. Data displayed in the table are IC50 values with confidence intervals (CI) 
 given in parentheses (n = 3–6). Statistical significance was determined by an F test by comparing fits in 
 which selected values were constrained to be equal or were allowed to differ. The null hypothesis was that 
 the best-fit parameter for the value did not differ. A conclusion of statistical significance represents a 
 rejection of the null hypothesis and indicates a difference between designated values 
 
The Affinity of Substrates, but Not Inhibitors, for Binding to hNET or hDAT Is Increased 
in Thr mutants.  To determine if Thr58 contributes to the binding of substrates and inhibitors, 
we tested substrate and inhibitor competition of whole cell [
3
H]nisoxetine binding to NET and its 
mutants.  When the binding assays were performed at room temperature, as were the [
3
H]DA 
uptake assays, the pattern of change in affinity of substrates mirrored that of the [
3
H]DA uptake 
studies.  There was no change in Kd for [
3
H]nisoxetine among the three mutants.  The Kd values 
for hNET (n = 3), T58A-hNET (n = 5), and T58D-hNET (n = 5) were 3.3 ± 1, 4.6 ± 0.6, and 7.0 




AMPH (p < 0.02) for T58D-hNET were significantly greater than that for hNET.  There was no 
change in affinity for NE in T58D-hNET, but there was a reduction in the fraction of 
[
3
H]nisoxetine binding sites that the catecholamine could access.  In hNET, 18% (95% CI, 7.9-
27) of the total [
3
H]nisoxetine binding sites were inaccessible to maximal concentrations of NE 
as compared to 45% (95% CI, 34-55) of the total binding sites in T58D-hNET (p < 0.005, F1,30 = 
15.16).  There was no significant change in affinity for DA or AMPH at T58A-hNET as 
compared with hNET.  As shown in the lower panels of Table 2-3, there was no change in 
potency for any inhibitor measured, including desipramine, for T58A-hNET or T58D-hNET as 
compared to hNET. 
A similar result was seen with the Thr-62 mutations in hDAT (Table 2-4).  The affinity for both 
DA (p < 0.0001) and AMPH (p < 0.001) to compete for [
3
H]WIN 35,428 binding was greatly 
increased in T62D-hDAT as compared with hDAT.  Moreover, the potency of DA (p < 0.01) and 
AMPH (p < 0.002) was significantly increased in T62A-hDAT as compared to hDAT.  These 
data mirror the effects of the hDAT mutations on inhibitory potency for [
3
H]DA uptake, 
signaling that the substrate binding site is close to, if not identical, with the substrate transport 
site.  As shown in Table 2-4, there was no change in affinity of GBR12935 or benztropine to 
compete for [
3
H]WIN 35,428 binding to hDAT, T62A-hDAT or T62D-hDAT.  The Kd for 
hDAT, T62A-hDAT, and T62D-hDAT are 16 ± 2, 10 ± 1, and 7 ± 1 nM (± S.E.M), respectively 
(n = 3).  There was, however, an increase in affinity for binding of cocaine to T62D-hDAT (p < 






 Table 2-3. Affinity for substrates and inhibitors in competing for [
3
H]nisoxetine binding in hNET 
 mutants. 
 Data were calculated as a percent of total [
3
H]nisoxetine binding in the absence of competing substrate or 
 inhibitor and analyzed by nonlinear regression. Data displayed in the table are IC50 values with confidence 
 intervals (CI) given within parenthesis. The number of experiments (n) is given under the ligand. Statistical 
 significance was determined by an F test by comparing fits in which selected values were constrained to be 
 equal or were allowed to differ. The null hypothesis was that the best fit parameter for the value did not 
 differ. A conclusion of statistical significance represents a rejection of the null hypothesis and indicates a 
 difference between designated values. F test values and degrees of freedom are given only in cases of 
 statistical differences.   
 The Ki (nM) values (with CI) at RT for WT-, T58A-, and T58D-hNET are as follows: DA – 275 (105-719), 
 237 (68-851), and 25 (20-302); NE – 161 (73-357), 451 (319-636), and 99 (20-488); AMPH – 95 (31-296), 
 62 (23-163), and 11 (3.7-33); cocaine – 588 (201-1718), 1017 (480-2154), and 940 (291-3040); 
 desipramine – 5.4 (3.1-9.4), 7.4 (3.9-13.9), and 4.0 (0.82-19); benztropine – 1726 (1195-2492), 2474 
 (1589-3852), and 3494 (1294-9435).   
 The Ki (nM) values (with CI) at 4°C for WT-, T58A-, and T58D-hNET are as follows: DA – 238 (108-
 526), 64 (37-111), and 30 (2.2-417); NE – 327 (113-945), 306 (127-739), and N.S.; AMPH – 0.9 (0.53-
 1.8), 2.6 (1.9-3.7), and 2.9 (1.1-7.9); cocaine – 532 (420-674), 866 (355-2110), and 809 (137-4765); 






 Table 2-4. Affinity for substrates and inhibitors in competing for [
3
H]WIN 35,428 binding in hDAT 
 mutants. 
 Data were calculated as a percent of total [
3
H]WIN 35,428 binding in the absence of competing substrate or 
 inhibitor and analyzed by nonlinear regression. Data displayed in the table are IC50 values with confidence 
 intervals (CI) given within parenthesis. The number of experiments (n) is given under the ligand. Statistical 
 significance was determined by an F-test by comparing fits in which selected values were constrained to be 
 equal or were allowed to differ. The null hypothesis was that the best fit parameter for the value did not 
 differ. A conclusion of statistical significance represents a rejection of the null hypothesis and indicates a 
 difference between designated values. F-test values and degrees of freedom are given only in cases of 
 statistical differences. 
 The Ki (nM) values (with CI) at RT for WT-, T62A-, and T62D-hNET are as follows: DA – 1064 (598-
 1892), 332 (201-547), and 6.8 (1.9-246); AMPH – 311 (161-601), 44 (23-85), and 5.2 (2.8-9.6); cocaine – 
 ambiguous fit for all cell types; benztropine – 50 (31-83), 71 (28-181), and 104 (52-207); GBR12935 – 
 ambiguous fit for all cell types.   
 The Ki (nM) values (with CI) at 4°C for WT-, T62A-, and T62D-hNET are as follows: DA – 61 (20-185), 
 13 (6.5-25), and 6.7 (1.4-31); AMPH – 94 (49-183), 12 (4.8-29), and 71 (1.9-2630); AMPH + Zn
2+
 – 412 






The Affinity and Extent of Substrate Binding in T58D-hNET is Sensitive to Temperature.  
In some experiments, we performed [
3
H]nisoxetine binding assays on ice as described 
(Distelmaier et al., 2004) and found notable differences in binding characteristics when the 
assays were conducted at 4° versus room temperature.  The Kd values for [
3
H]nisoxetine binding 
in hNET, T58A-hNET, and T58D-hNET at 4° were 4.9 ± 1, 7.6 ± 0.7, and 6.7 ± 1 nM (± S.E.M), 
respectively.  These values were not different from each other and were not different from those 
measured at room temperature.  The IC50s for DA and NE in hNET were comparable and 
unchanged when measured at the two temperatures (Table 2-3), but the apparent affinity for 
AMPH was over 60-fold greater when assayed at 4°C (3 nM) as compared to room temperature 
(182 nM). The 95% confidence intervals and F-distributions for all IC50 values are given in 
Table 2-3.  In the T58A-hNET cells, the IC50 values for DA and AMPH were significantly 
reduced at 4°C as compared with RT, but there was no change in potency for NE.  IC50 values 
for DA and AMPH competition of [
3
H]nisoxetine binding in T58A-hNET cells at RT vs 4°C 
were for DA, 370 versus 89 nM, respectively, p < 0.05; for AMPH, 100 versus 5 nM, 
respectively, p < 0.0001.  Striking changes in competition for [
3
H]nisoxetine binding to T58D-
hNET were noted for all substrates between the two temperatures.  The affintiy for DA in T58D-
hNET at 4°C was not significantly changed from that measured at RT, but there was a striking 
change in the accessibility of the [
3
H]nisoxetine sites for which DA could compete.  Access of 
all three substrates to all of the sites labeled with [
3
H]nisoxetine in T58D-hNET cells was 
restricted (shown for AMPH in Figure 2-4).  DA could compete for only 30% of the 
[
3
H]nisoxetine binding sites at 4
o




T58D-hNET cells, the percent unbound for DA in competing for [
3
H]nisoxetine sites is 43% 
(95% CI, 25-61) at RT versus 70% at 4°C (96% CI, 65-75) (p < 0.002, F1,24 = 12.03).  The 
percentage unbound for AMPH at RT is 35% (95% CI, 26-42) versus 59% (95% CI, 54-64) at 
4°C (p < 0.0001 F1,63 = 23.73). In hNET and T58A-hNET, AMPH competed for more than 80% 
of the [
3
H]nisoxetine binding sites at 4°C, demonstrating that T58D-hNET was most severely 
compromised at the low temperature (Figure 2-4).  NE was unable to compete for [
3
H]nisoxetine 
binding sites in T58D-hNET at any concentration (Table 2-3).  In contrast to the sensitivity of 
substrate competition for temperature, there was no change in either potency or extent of 
competition for [
3
H]nisoxetine binding for the inhibitors desipramine or cocaine, at RT versus 
4°C. 
We examined whether substrate competition for [
3
H]WIN 35,428 binding in hDAT was similarly 
temperature sensitive.  The Kd values for [
3
H]WIN 35,428 binding in the hDAT mutants at 4°C 
were not different from one another and were not different from those measured at room 
temperature.  The Kd values for [
3
H]WIN 35,428 binding in hDAT, T62A-hDAT, and T62D-
hDAT at 4° were 20 ± 3, 12 ± 4, and 7 ± 4 nM (± S.E.M), respectively.  As shown in Table 2-4 
and Figure 2-5, the affinity for DA and AMPH was increased in both hDAT and T62A-hDAT 
when [
3
H]WIN 35,428 binding was measured at 4°C as compared with RT.  The IC50 value for 
DA competition for [
3
H]WIN 35,428 binding in hDAT was 1.3 µM at RT versus 73 nM at 4°C 
(p < 0.0005) and in T62A-hDAT was 460 nM versus 17 nM at 4°C  (p < 0.05). The IC50 value 
for AMPH competition for [
3
H]WIN 35,428 binding in hDAT was 390 nM at RT versus 113 nM 




and F-distributions for these values are given in Table 2-4.  The affinity of DA for [
3
H]WIN 
35,428 binding in T62D-hDAT was already very high and was not changed at 4°C.  The affinity 
of AMPH for T62D-hDAT at 4°C is compromised by the sharply reduced accessibility of 
AMPH, similar to that seen with hNET.  DA accessed 84% [16% unbound (95% CI, 4.7-28)] of 
the [
3
H]WIN 35,428 binding sites in T62D-hDAT at RT but accessed only 53% [47% unbound 
(95% CI, 39-55)] of the sites at 4°C (p < 0.0001 F1,29 = 22.48).  Likewise, AMPH accessed 73% 
[27% unbound (95% CI, 21-33)] of the total [
3
H]WIN 35,428 binding sites in T62D-hDAT at RT 
but could access only 29% (95% CI, 58-84)) of [
3
H]WIN35,428 binding sites at 4°C (p < 0.05 
F1,45 = 5.158).  These data suggest that at 4°C the transporter favors a conformation that can 
readily accommodate binding of inhibitors, but not substrates. 
 
 Figure 2-4. At 4°C, the accessibility of AMPH to [
3
H]nisoxetine binding sites is reduced in T58D-
 hNET compared with binding at room temperature (RT). hNET (■), T58A-hNET (▲), and T58D-
 hNET (◊) cells were incubated with 3 nM [
3
H]nisoxetine and indicated concentrations of AMPH (0–30 
 µM) for 90 min at ambient temperature (RT) or 30 min at 4°C. Data (n = 3–9) are calculated as 
 [
3
H]nisoxetine binding in the presence of different concentrations of AMPH and expressed as a percentage 






 Figure 2-5. Temperature-dependent changes in competition of AMPH for [
3
H]WIN 35,428 binding to 
 hDAT mutants are reversed by addition of Zn
2+
. The hDAT (A) T62A-hDAT (B), and T62D-hDAT (C) 
 cells were incubated with 4 nM [
3
H]WIN 35,428 at room temperature (●), on ice (□), or on ice in the 
 presence of 100 µM Zn
2+
 (■). Data (n = 3–9) are shown as a percentage of [
3
H]WIN 35,428 bound in the 
 absence of any AMPH (control) at the given concentrations of AMPH (0–10 µM). IC50 values, bottom-of-






 Rescues Substrate Binding at Low Temperature in T62D-hDAT.  The effect of 
conformation on transporter activity can be examined in DAT due to its sensitivity to the ion, 
Zn
2+
.  DAT, as opposed to NET, contains three residues in its extracellular loops that 
coordinately bind Zn
2+
 (Norregaard et al., 1998).  Upon binding to DAT, Zn
2+
 potentiates an 
uncoupled Cl
-
 conductance in DAT, which modulates the membrane potential such that DA 
uptake is restricted and DA efflux is enhanced (Meinild et al., 2004).  In the presence of Zn
2+
, the 
equilibria of mutant transporters that appear predominantly inward-facing, in which DA uptake 
is compromised, are shifted toward a more outward-facing conformation, resulting in
 
enhanced 
DA uptake (Chen et al., 2004a; Guptaroy et al., 2009; Loland et al., 2002).  We examined 
whether Zn
2+
 would shift the equilibrium of substrate binding at 4°C to more resemble the 
potency and availability for substrates to bind at RT.  As shown in Figure 2-5 and Table 2-4, the 
potency of AMPH for [
3
H]WIN 35,428 binding to hDAT was increased 3-fold when assayed on 
ice, but when 100 µM Zn
2+
 was present at 4°C, the curve was identical to that assayed at RT.  
The IC50 for AMPH at 4°C + Zn
2+
 was 494 nM (95% CI, 26-94) as compared to 113 nM (95% 
CI, 6-22) at 4°C (p < 0.02).  When the T62A-hDAT mutant was measured at 4°C, there was a 
significant reduction in the IC50 for AMPH but also a significant reduction in the percentage of 
binding sites accessed (11% unbound at RT (95% CI, 0.8-20) versus 36% unbound at 4
o
C (95% 
CI,31-47), p < 0.0004 F1,29 = 15.74).  As seen in Figure 2-5B, addition of Zn
2+
 at 4°C restored 
the potency of AMPH in T62A-hDAT cells to RT levels [IC50 at 4°C + Zn
2+
, 61 nM (95% CI, 
43-88); p < 0.01 compared to 4°C] and enhanced the accessibility of AMPH to [
3
H]WIN 35,428 
binding sites [percentage unbound at 4°C + Zn
2+




as compared to 4°C].  As shown in Figure 2-5C, the dramatic reduction in the ability of AMPH 
to access [
3
H]WIN 35,428 in T62D-hDAT cells was corrected when 100 µM Zn
2+
 was included 
at 4°C.  Inclusion of 100 µM Zn
2+
 in the assay significantly restored the accessibility of AMPH 
to [
3




44% unbound; p < 0.05, F1,46 = 4.233).  Zn
2+
 also 
appeared to restore the potency of AMPH to match that attained at RT but the difference in IC50 
values between 4°C and 4°C + Zn
2+
 [IC50, 13 nM (95% CI 3-45)]  was not statistically 
significant due to the variability in binding at 4°C. 
Benztropine and Cocaine Interact Differentially with T62D-hDAT.  Examination of the data 
in Table 2-2 and Table 2-3 reveal that, for assays conducted at RT, there is a strong concordance 
in IC50 values for inhibition of [
3
H]DA uptake with the IC50 values obtained for competition of 
radioligand binding.  This is true for substrates and generally true for inhibitors with the 
exception of the effects of cocaine and benztropine at T62D-hDAT.  The IC50 values for cocaine 
and benztropine in inhibiting [
3
H]DA uptake at T62D-hDAT was increased, showing a reduction 
in potency as compared to hDAT (Table 2-2).  On the other hand, this reduction in potency as 
compared to hDAT was not exhibited when cocaine and benztropine competed for [
3
H]WIN 
35,428 binding.  For these drugs there is discordance between their effectiveness in inhibiting 
DA uptake and their ability to bind to T62D-hDAT.  This is seen clearly in Figure 2-6, in which 
the dose response curves for inhibition of [
3
H]DA uptake in hDAT and T62D-hDAT are 
compared for those for competition with [
3
H]WIN 35,428 binding.  The IC50 for benztropine 
inhibition of [
3
H]DA in hDAT (126 nM; 95% CI, 58-271) does not differ from that of the IC50 
for  [
3




hDAT cells the IC50 for benztropine in inhibiting [
3
H]DA uptake (851 nM; 95% CI 514-1411) is 
significantly greater than that for competition of [
3
H]WIN 35,428 binding (163 nM; 95% CI 81-
325, p < 0.002).  Likewise, in hDAT cells, the IC50 for blockade of [
3
H]DA uptake by cocaine 
(253 nM; 95% CI 127-505) is the same as that for competition for [
3
H]WIN35,428 binding (223 
nM; 95% CI 121-411).  In T62D-hDAT cells, the difference between inhibitory potency and 
binding potency for cocaine is greater than that for benztropine, primarily due to an enhancement 
in binding potency for cocaine as compared to wild type.  The IC50 for cocaine in inhibiting 
[
3
H]DA uptake in T62D-hDAT cells (1130 nM (95% CI 536-2380)] is significantly greater than 
the IC50 for competing with [
3





 Figure 2-6. Dissociation of benztropine and cocaine potencies for [
3
H]DA uptake and competition for 
 [
3
H]WIN 35,428 binding T62D-hDAT cells. Dose-response curves representing potency of benztropine 
 (top) and cocaine (bottom) for inhibition of [3H]DA uptake (■) and competition for [
3
H]WIN35,428 
 binding (□) binding in hDAT (left) and T62D-hDAT cells (right). The assays were conducted as described 
 under Materials and Methods. Data (n = 3–12) are shown as percentage of value in the absence of 
 benztropine or cocaine (control). IC50 values are given in Table 2-2 and Table 2-3. Statistical comparisons 
 of IC50 values for inhibition of DA uptake versus [
3
H]WIN 35,428 competition in T62D-hDAT: for 
 benztropine, p < 0.002, F1,52 = 11.65; for cocaine, p < 0.0001, F1,47 = 18.33. For both cocaine and 







The bidirectional transport of substrates through monoamine transporters and their interaction 
with therapeutic and abused psychostimulant drugs is conformation-dependent.  Emerging 
evidence indicates that interactions between specific transporter residues are critically important 
for maintaining relevant conformations and, when disrupted by mutations, impact transporter 
function. Here we show that mutations in a conserved N-terminal threonine residue of DAT and 
NET, alters transporter conformation and function. 
The juxtamembrane threonine residue (T62 in DAT, T58 in NET) resides in the RETW motif 
which is a putative phosphorylation site for protein kinase C/A/G, although phosphorylation at 
this site has not yet been shown. We demonstrated that mutations that mimic the phosphorylation 
state of this threonine residue have profound effects on the conformation and function of DAT 
(Guptaroy et al., 2009).  This intracellular threonine residue is not part of the substrate-binding 
site and presumably affects the permeation pathway indirectly through its effect on the 
interaction of critical residues.  An elegant study exploring the nature of the conformational 
changes associated with substrate transport in LeuTAa demonstrated that movement of the amino 
acid residue at position 7 of the N-terminal is associated with opening and closing of the inward 
gate (Zhao et al., 2010).  In LeuTAa the histidine residue at position 7 in the REHW motif 
corresponds to the threonine residue in RETW of DAT and NET and could potentially be critical 
in intracellular gating in monoamine transporters. In addition, these residues are adjacent to those 
involved in a conserved interaction network at the intracellular gate, which in DAT includes 




demonstrated that a mutation at Thr62 in hDAT disrupts its interaction with Lys260, which is 
adjacent to Val259, and consequently affects the interaction between Val259 and Tyr335 
(Guptaroy et al., 2009).  The greater structural disruption of the aspartate mutant as compared 
with the alanine mutant was reflected in their functional activities.  The data suggested that 
T62D-hDAT preferred an inward-facing conformation. We now demonstrate that corresponding 
mutations in NET result in similar but not identical phenotypes, although the overall 
conformational changes are probably similar.  Differences could be due the inherent 
dissimilarities between the two structures.  It is suggested that both alanine and aspartate mutants 
of the homologous threonine residue in the serotonin, DA, and NE transporters promote an 
inward facing conformation and lack AMPH-stimulated efflux (Sucic et al., 2010).  Though our 
data for the aspartate mutants in DAT and NET agree with these findings, we have consistently 
detected AMPH-stimulated DA efflux in the alanine mutants, although to a lesser extent than in 
the wild-type transporter.  The reduced efflux in T58A-hDAT could be due to a slow outward 
transition rate, resulting in a conformation that could be more inward-facing than that of hNET.  
However, the overall nature of interaction of substrates and inhibitors with the alanine mutants 
remained similar to the wild type transporter, leading us to conclude that the conformation of the 
alanine mutants of hDAT and hNET retains similarity to the wild-type transporter.  
DA influx activity diverges between DAT and NET in the alanine mutants, although efflux 
properties are similar. In T62A-hDAT, both influx and AMPH-stimulated efflux of DA were 
reduced, and this was attributed to a slowing of the transition between the inward and outward 




effects on DA influx (increased) and efflux (reduced).  The rate of inward and outward transition 
might also be affected in T58A-hNET. The N-terminal domains of DAT and NET have low 
homology and are of dissimilar lengths, which could contribute to differences between the 
uptake characteristics of T62A-hDAT and T58A-hNET. The alanine mutation may affect the 
interaction of diverse proteins with hDAT and hNET or differentially affect the interaction with 
the same protein.  
In both hNET and hDAT, the aspartate mutation increased the potency for DA and AMPH to 
inhibit [
3
H]DA uptake and compete for radioligand binding. The alanine mutation behaved 
similarly, except for substrate binding in hNET.  The general concordance of potency in function 
and binding suggests that the conformation elicited by either the Ala or Asp mutations increases 
the affinity for substrates at their binding site.  An increase in accessibility of the substrates is 
unlikely because the substrate potency for transporter binding was enhanced at 4°C, but 
accessibility to the binding sites was often reduced.  Nor is it likely that there is a defect in 
reorientation of the DA-transporter complex to an outward-facing form, which would kinetically 
result in an increased potency for substrates (Chen et al., 2004a), because basal efflux of [
3
H]DA 
was enhanced in both T58D-hNET (Figure 2-2A) and T62D-hDAT (Guptaroy et al., 2009).  The 
apparent affinity for substrates was also increased in Y335A-hDAT and D345N-hDAT, which 
are postulated to prefer a predominantly inward-facing conformation (Chen et al., 2004a; Chen et 
al., 2001; Loland et al., 2002).  Increases in functional and binding potencies were most notable 
for AMPH.  Potency for NE was only enhanced for inhibition of [
3
H]DA uptake in the aspartate 




variations of the substrates.  Because of the benzene-diol and the α-hydroxy side chain group, 
NE would have more points of attachment within the binding pocket than would AMPH (Indarte 
et al., 2008).  Fewer required attachment points for the non-catechol AMPH may permit the 
substrate to more easily attain an energetically favorable ligand pose within the binding pocket. 
The effect of conformational restriction on substrate binding was further demonstrated by 
measurement of radioligand binding at 4°C.  At 4°C, the conformation of hNET or hDAT was 
restricted into one resembling an inward-facing conformation, because the potency of substrates, 
especially AMPH, was significantly increased as compared with RT values.  The mobility of the 
aspartate mutants was severely compromised such that substrates could not access all 
[
3
H]radioligand binding sites, but inhibitor binding was unaffected.  The restoration of AMPH’s 
access to [
3
H]WIN 35,428 binding sites in hDAT as well as the reduction of AMPH’s binding 
potency to RT values by Zn
2+
 strongly indicates a limited mobility of an inward-facing 





binding by countering the defect in outward reorientation of the transporter (Chen et al., 2004a).  
However, a reduced potency for DA was observed at 4°C by Bonnet et al. (1990), but this study 
was performed in rat striatal membranes.  No temperature-dependent difference was observed in 
the Ki for DA binding in hDAT-transfected human embryonic kidney 293 cells (Chen et al., 
2001) but we saw no difference in the Ki for hNET.  The reason for the increased potency for 




The threonine mutations affected substrates more strongly than tested inhibitors (Figure 2-7), 
with the exception of cocaine and benztropine effects on hDAT.  In particular, there was no 
effect of the mutations on the function or binding of desipramine or nisoxetine in hNET or on 
GBR12935 in hDAT.  The structure of LeuTAa suggests a separation in substrate and some 
inhibitor binding in transporter proteins (Singh, 2008).  Within LeuTAa, a secondary binding site 
located extracellularly to the substrate binding site (Shi et al., 2008) serves as a vestibule for 
binding antidepressants (Singh et al., 2007; Zhou et al., 2007).  On the basis of these results, 
homology-based molecular modeling identified two putative binding pockets in NET and DAT: 
one which binds cocaine and corresponds to the leucine binding site and another similar to the 
clomipramine binding site in LeuTAa (Ravna et al., 2009).  Interaction between residues further 
into the lipid bilayer in TM1 are predicted to be altered in the interaction with tricyclic 
antidepressants including desipramine (Henry et al., 2007) and may not be as severely affected 
by these threonine mutations. 
The modification of the substrate binding site in the threonine mutants may account for the 
altered activity of benztropine and cocaine in the aspartate mutants.  Molecular modeling of 
DAT suggests that the binding sites of DA, AMPH, cocaine, and benztropine-like drugs overlap 
and correspond to the substrate binding site in LeuTAa that is distinct from the antidepressant 
binding pocket (Beuming et al., 2008).  These drugs are weak inhibitors at hNET, so their 
binding to hNET may not have been affected by the aspartate mutation.  The impaired ability of 
cocaine and other inhibitors to inhibit DA uptake in Y335A-DAT was attributed to its shift to an 




and stabilizes transporters in their outward-facing conformation (Chen and Justice, 1998; Loland 
et al., 2004).  Other inward-facing mutants of hDAT (D345N, D436A, and K264A) show similar 
but less dramatic decreases in the inhibitory potency of cocaine (Chen et al., 2004a; Loland et al., 
2004).  Our data suggest that cocaine and benztropine bind normally to T62D-hDAT but have a 
reduced potency in inhibiting DA uptake.  There is, therefore, discordance between inhibitor 
radioligand binding and function.  A lack of correlation has been observed previously in cocaine 
potency for inhibition of uptake and binding in wild-type DAT (Wang et al., 2003).  It cannot be 
excluded that disruption of the normal translocation cycle in mutant transporters causes uptake 
and binding affinities to diverge.  These results support the notion that the DAT conformation 
responsible for inhibitor high-affinity binding is less responsible for DA uptake (Wang et al., 
2003).  In some DAT mutants, cocaine and benztropine interactions differ (Chen et al., 2004b; 
Loland et al., 2008; Schmitt et al., 2008; Ukairo et al., 2005).  Because both cocaine and 
benztropine compounds contain tropane rings, the altered conformation of T62D-hDAT may 
affect side-chain associations with this ring structure.  It is unclear why the binding potency of 
cocaine is increased in T62D-hDAT.  It could be that T62D-hDAT rapidly oscillates between 
inward and outward states-a condition supported by its enhanced basal efflux, which is 
contingent upon the transporter more readily assuming an outward conformation.  
The above evidence strongly argues for a critical role of the highly conserved threonine residue 
in the juxtamembrane N-terminal domain of monoamine transporters in determining transporter 






 Figure 2-7. Chemical structure of substrates and inhibitors. These include substrates dopamine, 
 norepinephrine, and amphetamine and inhibitors cocaine and the cocaine analog WIN 35,428, benztropine, 
 GBR-12935, desipramine, and nisoxetine. 
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AN N-TERMINAL THREONINE MUTATION PRODUCES AN EFFLUX FAVORABLE, 
SODIUM-PRIMED CONFORMATION OF THE HUMAN DOPAMINE 
TRANSPORTER 
Abstract  
The dopamine transporter (DAT), a protein integral for clearing extracellular dopamine (DA), 
translocates DA between extracellular and intracellular environments through a series of 
conformational transitions.  Mutagenesis of Thr 62, a residue adjacent to transmembrane 1a, to 
alanine (T62A) or aspartate (T62D) revealed that T62D-hDAT partitions in a predominately 
inward facing conformation, while T62A-hDAT functions more similarly to wild type (WT)-
hDAT.  Compared to WT, T62D-hDAT exhibited reduced [
3
H]DA uptake, enhanced baseline 
DA efflux and no efflux in response to amphetamine (AMPH).  Here, we further investigate the 
basis of the mutants’ altered function with respect to substrate uptake, membrane conductance 
and Na
+
 requirements.  Confocal microscopy experiments reveal identical intracellular 
accumulation of the fluorescent DAT substrate, ASP
+
, in WT-, T62A- and T62D-hDAT-
HEK293 cells.  In the absence of substrate, identical membrane polarization was demonstrated in 
Xenopus oocytes expressing the T62 mutants.  However, substrate-induced inward currents were 
present in oocytes transfected with WT and T62A-, but not T62D-hDAT.  Replacement of 
extracellular sodium (Na
+
e) was used to evaluate shifts in the sodium gradient facilitation of 
DAT transport functions.  The EC50 for Na
+
e stimulation of [
3




three constructs expressed in HEK-293 cells.  As expected, decreasing [Na
+
]e  stimulated  
[
3
H]DA efflux in WT and T62A-hDAT cells.  Conversely, the enhanced [
3
H]DA efflux in T62D-
hDAT cells was independent of Na
+
e and was commensurate with [
3
H]DA efflux induced in WT 
cells either by removal of Na
+
e or by AMPH.  We conclude that Thr-62 is important for 
conformational stability of DAT, and that T62D-hDAT represents an efflux willing, Na
+
-primed 
orientation.  Possibly, T62D-hDAT represents an experimental model of the conformational 
impact of AMPH exposure to hDAT. 
Introduction 
The dopamine transporter (DAT) has a critical role in the regulation of dopamine (DA) 
neurotransmission due to its primary function of taking up released DA from the extracellular 
space back into the presynaptic nerve terminal.  DAT is also the site of action for therapeutic and 
abused psychostimulants such as amphetamine (AMPH) (Levi and Raiteri, 1993; Leviel, 2011).  
AMPH is a competitive DAT substrate that, upon translocation into the terminal, is capable of 
inducing reverse transport and subsequently increasing extracellular DA (Sulzer et al., 2005). 
The DAT is a member of the SLC6 family of transporters that require sodium and chloride ions 
for substrate translocation.  The electrochemical gradient of Na
+
 provides the energy required to 
move substrate through the transporter, against its concentration gradient (Chen et al., 2004b; 
Hahn and Blakely, 2007).  The alternate access model is the common paradigm for the 
translocation of neurotransmitter and co-transported ions (Jardetzky, 1966), where the transporter 




inside the cell.  Crystallization of the leucine transporter (LeuT), a bacterial SLC6 homologue 
(Krishnamurthy and Gouaux, 2012; Yamashita et al., 2005), has provided vast information about 
the transporter structure and translocation mechanism that further validate the alternate access 
model.  Elegant molecular modeling comparisons to hDAT have identified fundamental 
transmembrane domains (TM) and amino acid residues involved in ligand binding and the 
extracellular to intracellular translocation of substrate (Shan et al., 2011; Zhao et al., 2012; Zhao 
et al., 2010).  However, the mechanisms regulating the binding of DA and co-transported ions 
during reverse transport are not fully understood. 
The DAT N-terminus contains various serine and threonine residues that are important for the 
regulation of transporter activity (Foster et al., 2002) and AMPH-induced DA efflux (Foster et 
al., 2012; Khoshbouei et al., 2004).  We were interested in studying the threonine residue within 
the highly conserved, RETW sequence of the DAT N-terminus to gain further insight into the 
mechanisms of AMPH action.  The RETW sequence is juxtaposed to the TM1a segment 
(Yamashita et al., 2005), which is within a DAT region identified as the intracellular gating 
network (Kniazeff et al., 2008).  To study this site, the Thr 62 residue of DAT was mutated to an 
alanine (T62A) or aspartate (T62D) to mimic a non-phosphorylated and a phosphorylated state, 
respectively (Guptaroy et al., 2009).  Based upon previous findings, we have determined that the 
T62D mutation shifts the orientation of hDAT from a primarily outward to inward facing 
conformation. Our initial studies showed a reduction in the uptake of [
3
H]DA and a loss of 
AMPH-stimulated DA efflux in T62D-hDAT compared to WT hDAT HEK cells (Guptaroy et 




used to correct dysfunctions of other inward facing hDAT mutants (Loland et al., 2002; Meinild 
et al., 2004).  Other major differences from WT observed in T62D-hDAT cells were the increase 
in basal, unstimulated DA release, a faster rate of DA efflux, and a significantly reduced Km for 
[
3
H]DA efflux (Guptaroy et al., 2009).  Additional studies revealed an enhanced affinity for 
other substrates (norepinephrine, AMPH) in the Thr62 hDAT mutants cells (Guptaroy et al., 
2011), especially in the predominately inward facing T62D-hDAT HEK cells.  Enhanced 
substrate affinity is likely when the transition of substrate-bound transporter from the inward to 
outward orientation is kinetically favored, as deemed with inward-facing mutant transporters 
(Chen et al., 2004a; Guptaroy et al., 2011; Guptaroy et al., 2009).         
In this study we used the T62D-hDAT as a model to further investigate the influence of 
transporter orientation on the membrane potential and the requirements of Na
+
 for DAT 
functions.  We hypothesized whether the elevated basal DA efflux measured in T62D-hDAT 
HEK cells could be attributed to 1) poor intracellular accumulation of substrate; 2) an intrinsic 
depolarized membrane; or 3) a modification in Na
+
 gradient.  These hypotheses were tested 
using a combination of electrophysiology measurements in Xenopus oocytes, and radioligand 
and fluorescent microscopy techniques in heterologous cells.  The results from these experiments 
strengthened the conclusion that T62D-hDAT partitions in a predominantly inward-facing state 
and, moreover, that the conformation represents an inward ‘Na
+





Materials and Methods 
Cell culture 
Wildtype, T62A, and T62D mutant human dopamine transporter (hDAT) were cloned and stably 
expressed in human embryonic kidney 293-T cells as previously described (Guptaroy et al., 
2009). Cells were maintained in high glucose Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37° C and 5% 
CO2.  All experiments utilizing hDAT HEK cells were performed with intact, attached cells at 
room temperature. 
Confocal Microscopy and Image Analysis 
Accumulation of the fluorescent substrate ASP
+
 [4-(4-(Dimethylamino)styryl)-N-
methylpyridinium] (Molecular Probes, Eugene, OR) was measured with confocal imaging in live 
WT and Thr mutant hDAT HEK cells.  Cells were plated on poly-D-lysine (PDL) coated, 35 mm 
glass bottom MatTek culture dishes (MatTek, Ashland, MA) at a density of 500-750,000 cells 
per dish 1 day prior to imaging.  The culture media was aspirated and cells were washed twice in 
normal Krebs Ringer’s HEPES (KRH) buffer, pH 7.4 [in mM: 125 NaCl, 4.8 KCl, 1.2 KH2PO4, 
1.3 CaCl•2H2O, 1.2 MgSO4·7H2O, 5.6 glucose, and 25 HEPES] containing 50 µM of pargyline 
(MAO inhibitor), 1 mM tropolone (COMT inhibitor), and 50 µM ascorbic acid (DA antioxidant) 
(Sigma, St. Louis, MO).  Cells were incubated at 37° C in 2 ml of 5 µg/ml Hoechst nuclear stain 
(Molecular Probes) for 30 min.  Then cells were washed twice quickly and then twice more for 5 




FluoView 500 confocal microscope and focused in 100 µl KRH to take the differential 
interference contrast (DIC) image.  The center of the cell plane was determined with the nuclear 
stain.  A test plate of WT-hDAT HEK cells was used to set the levels for intensity, brightness, 
and contrast for minimal saturation of the fluorescent signal of each laser channel. These 
microscope settings were not adjusted during the image acquisition of experiment plates.  The 
Hoechst stain was excited with a UV laser at 405 nm and passed through a BA430-460 bandpass 
filter.  ASP
+
 was excited using the Hene-green laser with excitation at 543 nm and a BA610IF 
bandpass filter.  Images were acquired at room temperature with a time scan every 10 sec for 3 
min.  ASP
+
 (2 µM, 2 ml) was carefully added to the cells after the first 10 sec acquisition.  The 
average fluorescence intensity (AFI) within whole cell regions was identified and quantified with 
MetaMorph image acquisition software v. 7.71 (Molecular Devices, Sunnyvale, CA).  By the end 
of image acquisition (3 min), the background fluorescence in parental HEK cells was around 
80% of the ASP
+
 fluorescent signal in cells expressing WT or Thr 62 mutant hDAT. 
ASP
+ 
Competition of Radiolabeled Dopamine and WIN 35, 428  
Cells were seeded onto 24-well plates at a density of 200,000 cells per well 1 day before the 
experiment.  Uptake of 10 nM [
3
H]DA (specific activity 46 Ci/mmol) for 3 min or binding 
displacement of [
3
H] WIN 35,438 (specific activity 85 Ci/mmol) for 30 min (Perkin Elmer 
Waltham, MA) were measured at room temperature in ASP
+
 concentrations ranging from 0 to 1 
mM prepared in KRH buffer containing 10 % DMSO.  Non-specific uptake or binding was 




minute preincubation with the inhibitor alone.  At the end of the assay, cells were washed 4 times 
in ice cold PBS then lysed in 0.25 ml 1% SDS.  Radioactivity was measured in 5 ml of 
Scintiverse cocktail (Fisher Scientific, Waltham, MA) using a Beckman LS5801 scintillation 
counter (Fullerton, CA).   
Extracellular Sodium Substitution 
For extracellular sodium substitution experiments, the NaCl in the KRH buffer was replaced with 
N-methyl-D-glucamine chloride (NMDG-Cl).  [
3
H]DA uptake was measured as stated above, 
while varying the levels of Na
+
e.  Assay buffer with 0, 10, 30, 50, 100 and 125 mM NaCl 
contained 125, 115, 95, 75, 25, and 0 mM of NMDG-Cl, respectively.  Maximum uptake was 
obtained in the normal, 125 mM NaCl condition for all constructs. 
For efflux experiments, cells were preloaded with 0.5 µM DA (containing 15 nM [
3
H] DA) in 
normal KRH.  After washing, 0.25 ml of fresh Na
+
 substituted KRH was collected and replaced 
for 15 min to evaluate the baseline DA efflux.  The Na
+
e effect of AMPH-induced DA release 
was determined after a 5 min application of 10 µM AMPH, followed by collection of an 
additional 5 min aliquot at 20 min.  At the end of the assay, cells were solubilized to measure the 
final amount of DA remaining inside of the cells after efflux.  Total [
3
H]DA after preloading was 
estimated as the sum of radioactivity in all efflux fractions and final intracellular DA.  Basal DA 
efflux was taken as a percentage of the estimated total [
3
H]DA.  AMPH-induced [
3
H]DA efflux 
was calculated as a percentage of the total [
3




Molecular Biology of hDAT Expression and Electrophysiology Measurements in Xenopus 
Oocytes 
Restriction enzyme sites for 5’ NotI and 3’ XbaI were added to the flag-tagged WT and Thr62 
hDAT mutant DNA constructs (Guptaroy et al., 2009) and subcloned into the pSGEM Xenopus 
oocyte expression vector. After linearization of the plasmid with SbfHI-HF digestion (New 
England BioLabs Inc., Ipswich, MA), capped RNA (cRNA) was prepared according to protocol 
with the mMessage mMachine T7 kit (Ambion Inc., Ausin, TX).  Stage V oocytes were 
microinjected with 23 ng of water or 1ng/nl hDAT cRNA and incubated at 18° C in 
SuperBarth’s solution, pH 7.4 [in mM: 88 NaCl, 1 KCl, 0.33 Ca(NO3)2·4H2O, 0.41 CaCl2 
·2H2O, 1 MgSO4·7H2O 2.4 NaHCO3, 10 HEPES, 1 Na-Pyruvate, and 50 mg/ml gentamicin] for 
4-8 days before electrophysiology recordings.  Unless otherwise noted, oocytes were voltage 
clamped at -60 mV.  Current was recorded continuously with perfusion of DA or AMPH.  The 
perfusion solution contained (in mM) 93.5 NaCl, 2.0 KCl, 1.8 CaCl2, 2.0 MgCl2, 5.0 HEPES, pH 
7.5.  Recording electrodes had 1-5 MΩ resistance and were filled with 3M KCl.  Current 
measurements were analyzed with ORIGIN 6.0 software.  The electrophysiology experiments 
with oocytes were performed by Dr. Yongyue Chen in the laboratory of Dr. Louis DeFelice at 
the Virginia Commonwealth University, Richmond, VA.  
Statistical Analysis 
Dose-response curves were analyzed with GraphPad Prism 6 software (San Diego, CA) to 
determine the IC50 and EC50 values for [
3




analyses.  Statistical differences were compared between constructs testing the null hypothesis of 
the parameter being the same between all data sets.  A rejection of the null hypothesis indicated a 
statistical difference between the comparisons, where the p value was below 0.05.  Values are 
provided ± standard error of the mean (s.e.m) along with the 95% confidence intervals. 
Results 
Affinity and Accumulation of the Fluorescent Substrate, ASP
+
 in WT and Thr hDAT 
Mutant HEK Cells.  The uptake and binding properties of the ASP
+
 substrate to hDAT were 





H]DA uptake (Figure 3-1A) and displacement of the cocaine analog [
3
H]WIN 35, 428 
(Figure 3-1B) did not differ between WT and Thr 62 hDAT mutant cell lines.  The IC50 values 
(µM) [with 95% confidence intervals] for ASP
+
 competition of [
3
H]DA uptake (Figure 3-1A) 
were 11.95 [8.87-16.1] in WT-, 17.60 [10.6-29.2] in T62A-, and 12.08 [10.3-14.1] in T62D-




H]WIN 35,428 binding with IC50 (µM) values of 11.95 
[8.87-16.1] in WT-, 18.6 [10.6-29.2] in T62A-, and 12.1 [10.3-14.1] in T62D-hDAT HEK cells 





 Figure 3-1. Affinity of the fluorescent substrate, ASP
+
 is unaffected by the T62A or T62D hDAT 
 mutations.  As detailed under Materials and Methods, A. uptake of 10 nM [
3
H]DA for 3 min or B. binding 
 of [
3
H]WIN35,428 for 30 min in WT- (■), T62A- (▲), and T62D-(◊) hDAT HEK cells was measured as a 
 function of varying ASP
+
 concentrations.  Data are expressed as the percent of the control without ASP
+
; 
 and are shown as the mean ± s.e.m, n = 2 experiments performed in triplicate. The IC50 (µM) values with 
 95% confidence intervals are reported in the text of the Results. 
In previous studies (Guptaroy et al., 2009), we found that T62D-hDAT demonstrated high 
affinity, but very low Vmax [
3
H]DA uptake with high basal efflux.  We postulated that substrate 
would not accumulate intracellularly due to accelerated outward transport.  Km and Vmax values 
for [
3
H]DA uptake for T62A-hDAT were intermediate between T62D-hDAT and WT (Guptaroy 
et al., 2009).  We measured uptake of the fluorescent substrate 4-(4-(dimethylamino)styryl)-N-
methylpyridinium (ASP
+
), which has been often studied as a substrate for DAT (Bolan et al., 
2007; Schwartz et al., 2003; Zapata et al., 2007).  ASP
+
 is structurally similar to the 
dopaminergic neurotoxin, 1-methyl-4-phenylpyridinium (MPP
+
).  Because ASP
+
 is bound to 
mitochondria, it is not subject to rapid outward transport (Schwartz et al., 2003), which allows 
more accurate measurement of influx in the T62D-hDAT mutant.  There was a small amount of 
background fluorescence prior to the addition of ASP
+




increased with time after cells were exposed to 2 µM of ASP
+
.  The full range of intracellular 
ASP
+
 accumulation at each time point is shown in Figure 3-2E.  Although the average 
fluorescence intensity in cells with transporter is approximately 20% greater, the accumulation in 
parental HEK cells lacking DAT was on average 70% of WT-, 84% of T62A-, and 80% in 
T62D-hDAT HEK cells.  The reason for high background fluorescence in empty HEK cells is 
not clear and is under investigation.  The time dependent increase of ASP
+
 fluorescence in 
T62A- and T62D-hDAT HEK cells were comparable to levels of WT-hDAT HEK cells.  It 
should be noted, however, that by biotinylation measuring surface DAT, T62D-hDAT is 
expressed to only 50% of the level as hDAT (Guptaroy et al., 2009), thus there are 50% fewer 
transporters on the surface to take up ASP
+
.  Despite the diminished number of transporters, the 
rate of uptake of ASP
+







 Figure 3-2. Accumulation of fluorescent substrate, ASP
+
 in T62A- and T62D-hDAT HEK cells.  
 Representative confocal images of time dependent ASP
+
 accumulation are displayed in columns A. WT-, 
 B. T62A-, and C. T62D-hDAT, and D. parental HEK cells.  Acquired representative images at time 0 and 
 180 sec after exposure to 2 µM ASP
+
.  E. The average fluorescence intensity was quantified in intracellular 
 regions of WT- (■), T62A- (▲), and T62D-(◊) hDAT HEK cells using Metamorph Imaging software.  





Current Measurements in Xenopus oocytes.  Depolarization of the membrane is known to 
favor efflux or reverse transport of monoamine substrates (Rutledge, 1978; Zhen et al., 2005).  
We next tested whether elevated efflux in T62D-hDAT HEK cells was the result of an intrinsic 
depolarization of the membrane by the T62D conformation utilizing the Xenopus oocyte 
expression system.  Oocytes were injected with equal concentrations of cRNA and DAT 
expression was confirmed by [
3
H]DA uptake assays in 5 individual oocytes.  DA uptake in 
hDAT-expressing oocytes was approximately 40% greater than in control, water injected oocytes 
4 days after cRNA injections (data not shown). 
The resting membrane potential (RMP) was first measured in oocytes expressing the 
transporters.  The RMP in control oocytes injected with water was  around -40 mV.  Expression 
of WT-, T62A-, or T62D-hDAT depolarized the recorded RMP to -25 mV (Figure 3-3).  The 
level of depolarization induced by T62A- or T62D-hDAT expression in the oocytes was the 
same as WT-hDAT.  The well characterized leak current present in DAT in the absence of 
substrate (Sonders et al., 1997) is likely accountable for the depolarization of the oocyte.  The 
RMP recordings suggest the baseline current passing through the transporter in the absence of 





 Figure 3-3. Expression of WT-, T62A-, and T62D-hDAT mutants causes similar membrane 
 depolarization in Xenopus oocytes.  X. oocytes were injected with 23 ng of cRNA for WT, T62A or T62D 
 hDAT.  Expression of hDAT reduces the recorded resting membrane potential of oocytes when compared 
 to control oocytes injected with 23nl or water. 
 
Substrate translocation via DAT is an electrogenic process that produces measureable currents.  
Substrates like AMPH and DA are known to induce inward currents that are primarily attributed 
to an inward flux of Na
+
 ions (Sonders et al., 1997).  We next measured the substrate-induced 
currents in WT-, T62A- and T62D-hDAT oocytes.  Representative trace recordings from oocytes 
voltage clamped at -60 mV are shown in Figure 3-4A.  Currents were measured after the 




expressing WT-hDAT that were absent in control oocytes lacking the transporter.  T62A-hDAT 
oocytes also produced DA-induced inward currents, although the current magnitude was nearly 
half that measured in WT-hDAT oocytes.  This finding corresponds with our previous reporting 
of a near 50% reduction in the Vmax for [
3
H]DA uptake in T62A-hDAT HEK293 cells as 
compared to WT-hDAT HEK293  cells (Guptaroy et al., 2009).  No current was detected in 
T62D-hDAT oocytes (Figure 3-4).  Zinc has been used in numerous studies to reverse the 
defective translocation of T62D-hDAT HEK293 cells (Guptaroy et al., 2011; Guptaroy et al., 
2009) and other inward facing DAT mutant transporters (Chen et al., 2004a; Loland et al., 2002).  
Binding of zinc stabilizes the outward facing conformation of DAT via an increase in chloride 
conductance (Loland et al., 2002; Meinild et al., 2004).  We utilized zinc to determine if 
substrate-induced currents could be measured in T62D-hDAT oocytes.  While Zn
2+
 alone 
produced a small current in T62D-hDAT oocytes, the co-application of 2 µM ZnCl2 and DA 
revealed a measureable current (Figure 3-4).  The current traces recorded with AMPH (20 µM) 
for each oocyte construct matched those measured using DA (data not shown). The DA induced 






 Figure 3-4. Dopamine-induced inward currents in T62D-hDAT oocytes are partially rescued by zinc. 
 A. Representative continuous traces of currents measured in oocytes clamped at -60 mV are shown.  
 Inward currents are observed in WT- and T62A-hDAT oocytes after application of 10 µM dopamine (DA).  
 Co-application of 2 µM ZnCl2 partially restored a measurable inward current in T62D-hDAT oocytes.  B. 
 Shows the change in accumulated current in WT-, T62A-, and T62D-hDAT oocytes held at -60 mV.  The 
 data are expressed as the average ± s.e.m with numbers of oocytes for each condition given.  The effects of 
 zinc alone in all constructs can be seen in Figure 3-5. 
 
The currents in WT-, T62A-, and T62D-hDAT oocytes were measured over a range of 
membrane potentials from -150 to 30 mV.  The current-voltage (I-V) relationships are shown in 
Figure 3-5.  DA-induced inwards currents were detected at hyperpolarizing potentials (Ingram et 
al., 2002; Sonders et al., 1997) in oocytes expressing WT- ( Figure 3-5A) or T62A-hDAT (Figure 




of zinc and DA resulted in a potentiation of the substrate-induced current in all three constructs.  
In T62D-hDAT oocytes (Figure 3-5C), DA-induced currents were only measurable in the 
presence of zinc. 
 
 Figure 3-5. Current-voltage relationships in hDAT expressing Xenopus oocytes.  A step voltage clamp 
 protocol was used from -150 to 30 mV at a holding potential of -60 mV and 10 mV step increments for 30 
 sec duration. Oocytes were challenged with 10 µM DA ± 2µM ZnCl2.  At hyperpolarizing potentials, DA 
 (black squares) induces an inward current in A. WT- and B. T62A-hDAT oocytes.  Co-application with 
 zinc (blue triangles) potentiates DA induced inward currents.  C. In T62D-hDAT oocytes, DA inward 
 currents are only measurable in the presence of zinc.  Application of zinc alone (red circles) produced a 
 small current in all constructs.  Each I-V plot was generated from 4-6 oocytes expressing the indicated 
 hDAT construct. 
 
The absence of net current measured in response to substrate in the T62D-hDAT mutant 
suggested that there was an equal flow of ions in both directions.  Because the inward current is 
likely a Na
+
 current, we were led to explore the effect of Na
+
 on the function of T62D-hDAT as 
compared to the other constructs.  This was addressed with studies measuring uptake and efflux 





Extracellular Sodium Substitution Experiments.  To determine whether the T62A or T62D 
mutations would alter the Na
+
 requirements for hDAT function, we measured [
3
H]DA uptake 





e).  NaCl was replaced with NMDG-Cl to maintain osmolarity of the 
cells.  In all cell lines, there was very little uptake of [
3
H]DA with complete NMDG-Cl 
substitution  (0 mM Na
+
e).  There was no statistical difference between the EC50 (mM) [95% CI] 
values for Na
+
 stimulation of [
3
H]DA uptake in WT- 39.6 [26.7-58.5], T62A- 40. 5 [29.7-55.1], 
or T62D- 58.7 [39.4-87.6] (Figure 3-6).  
 
 Figure 3-6. The reliance for extracellular Na
+
 to promote DA uptake is not altered by the Thr62 
 hDAT mutations. Extracellular sodium (Na
+
e) stimulation of [
3
H]DA uptake in WT- and T62 mutant 
 hDAT HEK cells.  Uptake of 10 nM [
3
H]DA was conducted for 3 min at room temperature.  Na
+
 in the 
 uptake buffer was replaced with NMDG-Cl to maintain osmolarity.  The IC50 (mM) for Na
+
e in WT, T62A, 
 and T62D was 39.6, 40.5, and 58.7, respectively.  Data are from n = 4 experiments done in triplicate and 







Outward transport through DAT demonstrates an inverse dependence on Na
+
e as compared to 
inward transport.  Removal or lowering of extracellular Na
+
 stimulates substrate efflux in cells 
expressing monoamine transporters (Pifl et al., 1997; Pifl and Singer, 1999) or brain tissue 
preparations (Liang and Rutledge, 1982; Raiteri et al., 1979) by shifting the internal Na
+
 gradient 
to favor reversal of the transporter.  Khoshbouei et al. (2003) demonstrated that the concentration 
of intracellular Na
+
 drives the ability of AMPH to induce DA release through DAT.  Previously 
we reported that T62D-hDAT had an elevated basal leak of [
3
H]DA which exceeded that of WT 
at physiological levels of Na
+
e (Guptaroy et al., 2009).  Here, the behavior of the basal efflux as a 
function of Na
+
e was examined. 
WT-hDAT HEK cells showed the expected elevation in basal [
3
H]DA efflux upon removal of 
Na
+
e and the elevation was maintained throughout the 15 min incubation period (Figure 3-7, 
open bars).  The baseline efflux significantly decreases as [Na
+
e] progresses from 0 mM, 10 mM, 
50 mM to 125 mM (Figure 3-7, white, checkered, gray, and black bars); indicating a return of the 
transporter from a predominantly inward-facing to an outward-facing conformation.  This same 
pattern recurred at the 10 min and 15 min time points (Figure 3-7, checkered, gray, and black 
bars).  In a 2-way ANOVA, there was a main effect of time (p < 0.01 (F (3, 56) = 5.755)) and a 
significant interaction between [Na
+
e] and time (p<0.0001 (F (9, 56) = 11.07)) with no main effect 
of [Na
+
e] (p=0.059, F (3, 56) = 2.625).  Significant stimulation of efflux by AMPH is only seen 
above the corresponding baseline at 50 mM Na
+
e (p < 0.05, n = 3, post hoc Tukey’s) and 125 
mM Na
+




The pattern was similar in T62A-hDAT HEK cells even though the degree of [
3
H]DA efflux was 
lower than in WT (Figure 3-7B).  By 2-way ANOVA, there was a significant effect of time (p < 
0.01, (F (3, 46) = 5.554)), and interaction of [Na
+
e] and time (p <0.001, F (9, 46) = 4.175), but no 
significant effect of [Na
+
e] (p=0.1528, F (3, 46) = 1.842).  As shown in Figure 3-7, addition of 
AMPH prevents [
3
H]DA efflux in WT-hDAT (Figure 3-7A, D) and T62A-hDAT (Figure 3-7B) 
cells under conditions of absent, 0 mM or low, 10 mM Na
+
e.  When the Na
+
 gradient favoring 
intracellular Na
+
 is less pronounced, that is, when [Na
+
e] is 50 mM or 125 mM, AMPH instead 
stimulates efflux in WT-hDAT and T62A-hDAT mutants (Figure 3-7A and B). 
In T62D-hDAT HEK cells, there was a significant effect of time by 2-way ANOVA (F (3, 51) = 
25.07) but no interaction with time and [Na
+
e] and no main effect of [ Na
+
e].  The basal [
3
H]DA 
efflux declined during the incubation period but was independent of  Na
+
 e (see legend Figure 
3-7D).  The decline in [
3
H]DA efflux was not due to a loss of intracellular [
3
H]DA since 70% - 
80% of the [
3
H]DA originally taken up was still inside the cell after 20 min.  AMPH does not 
induce [
3
H]DA efflux at any [Na
+
e] in the T62D-hDAT mutant, which remains inward-facing 
independent of Na
+
e (Figure 3-7C).  All values at the 20 min time point, which contained AMPH, 
were significantly different from values for 0 mM Na
+





 Figure 3-7. Initial [
3
H]DA efflux in T62D-hDAT is Na
+
 independent and resembles inducible DA 
 efflux of WT-hDAT HEK cells. A. WT-hDAT, B. T62A- and C. T62D-hDAT HEK cells were preloaded 
 with 0.5 µM [
3
H] DA (in normal buffer) for 20 min. Basal and AMPH-induced DA efflux were determined 
 while varying [Na
+
e].  After 15 min (green arrow), cells were stimulated with AMPH (10 µM) in varying 
 [Na
+
e] for 5min.  In WT (A), ** p < 0.01, * p < 0.05 for 0 versus 125 mM at times 5, 10, and 15 min; ++++ 
 p < 0.0001, +++ p < 0.001, + p < 0.05 for 20 min (after AMPH) compared to 15 min (before AMPH) at 
 each corresponding [Na
+
e] D. Comparisons of basal and AMPH (green arrow) DA efflux in WT- (circles) 
 and T62D-(squares) at 0 mM (open symbols) and 125 mM (closed symbols) Na
+
e.  To account for variation 
 in DA uptake, the data are represented as a percentage of the total [
3
H] DA inside of the cell after DA 
 preloading.  Data are from 3 experiments performed in triplicate.  Analyses of the 3-way interaction (time · 
 [Na
+
e] · cell type) is not significantly different between WT and T62D at 0 mM Na
+
 (with the exception of 
 15 min, p = 0.005) or at 125 mM Na
+
 (except the slight difference at 5 min, p = 0.054).  DA efflux after 
 AMPH (20 min) is significantly greater in WT compared to T62D at 125 mM Na
+
 (p < 0.0001), with no 
 difference between cell types at 0 mM Na
+
 ( p = 0.23).  The effect of Na
+
e on DA efflux was significant in 
 WT but not in T62D (p < 0.001, time · cell type · [Na
+
e]).  Analyses of cell type · [Na
+
e] · time shows a 
 significant change after the addition of AMPH (15 min versus 20 min) in WT at both 0 mM (p = 0.002) and 
 125 mM Na
+
 (p < 0.0001); and in T62D at 0 mM Na
+
 (p = 0.03), but not 125 mM (p = 0.235). 
 
In order to better visualize the similarities or differences between T62D hDAT and the inward 
(no Na
+
e) and outward (normal Na
+
e)-facing conformations of WT hDAT, data for only these 
two constructs at 0 mM and 125 mM Na
+




model 3-way ANOVA, there was a significant effect of time x cell type (F=10.277, df=3, 
p=0.0001, a significant time x sodium interaction (F=14.951, df=3, p=0.0001 and a significant 
time x cell type x sodium interaction (F=10.190, df=3, p=0.0001).  There was no significant cell 
type x sodium interaction (p=0.5).  At the initial time point of 5 min, the rate of [
3
H]DA efflux is 
identical for T62D hDAT at 0 and 125 mM Na
+
e (p = 0.647) and for WT at 0 mM Na
+
e (p = 
0.612).  It would appear that removal of Na
+
e constrained WT hDAT in an inward-facing 
position that is mimicked by T62D-hDAT independently of Na
+
e.  Regardless of [Na
+
e], the rate 
of [
3
H]DA efflux significantly declines between the 5 min and 20 min points for the T62D hDAT 
mutant (Figure 3-7D).  However, efflux in WT-hDAT remained stable between 5 and 15 min 
whether at 0 mM Na
+
e or 125 mM Na
+
e.  At the 20 min time point where AMPH is present, rates 
of [
3
H]DA efflux from WT-hDAT at 0 mM Na
+
e are equal to those of T62D-hDAT at any 
concentration of Na
+
e (Figure 3-7D, 20 min open circle, open & closed squares).  The rate of 
efflux of [
3
H]DA elicited by AMPH at the more physiological 125 mm Na
+
e or by 0 mM Na
+
e in 
WT-hDAT and was comparable to T62D hDAT, demonstrating the reversal back to the inward-
facing state.  We therefore reasoned the T62D hDAT mutation produces a Na
+
-primed state of 
the transporter that readily releases DA.  Another significant finding is the decrease in basal 





H]DA efflux was sensitive to inhibition by 100 μM cocaine in all three DAT constructs.  The 
fractional efflux of [
3
H]DA in the presence of 100 μM cocaine was constant within each 
construct independent of time and [Na
+
e].  Fractional [
3




cocaine is 6.4 ± 0.1 for WT, 7.3 ± 0.6 for T62A-hDAT, and 4.9 ± 0.2 for T62D-hDAT (n=4 each 




In this study, we delineate key characteristics of T62 DAT mutants that contribute to our 
understanding of DAT conformation regulation.  Our previous experiments led us to conclude 
that T62D-hDAT was predominantly partitioned in an inward-facing conformation (Guptaroy et 
al., 2009) and we postulated, but did not prove, that the extremely low Vmax of this mutant for 
[
3
H]DA uptake was due to rapid cycling of the transporter between inward- and outward-facing 
conformations.  In this study we confirm that hypothesis by demonstrating that T62D-hDAT can 
take up a non-effluxing substrate normally as compared to WT.  Moreover, we demonstrate that 
the mutation of Thr-62 to Asp-62 results in a conformation that represents the Na
+ 
-sensitive state 
of the inward gate.  In spite of having an orientation representing maximal responsiveness to 
internal Na
+
 with an unregulated, inwardly-open gate, T62D-hDAT is able to normally bind 
substrate in the outward-facing conformation and transition to inward-facing.  The outward-
facing conformation of T62D-hDAT retained Na
+ 
sensitivity equal to that of WT demonstrating 
the independence of Na
+
-dependent inward and outward-facing conformations. 
The use of the fluorescent substrate, ASP
+
, permitted interrogation of whether the Thr62 hDAT 
mutations truly disrupt the influx of substrate and, by inference, its intracellular retention.  ASP
+
 
has been well characterized as a substrate for both DAT and NET (Schwartz et al., 2003).  ASP
+
 




cells and not subject to efflux.  Once inside the cell, ASP
+
 sequesters within mitochondria 
(Schwartz et al., 2003) and, as a non-catechol substrate, will not bind to the inward-facing gate 
and be subject to outward transport (Liang et al., 2009).  The fact that ASP
+
 accumulation was 
identical in T62D-hDAT and WT-hDAT demonstrates normal (outward to inward) translocation 
in T62D.  Therefore, the extremely low Vmax of [
3
H]DA in T62D-hDAT cells (Guptaroy et al., 
2009) was due to continuous intracellular rebinding [
3
H]DA and its outward transport.  This 
finding distinguishes T62D-hDAT from other DAT mutants that have been characterized as 
being inward facing.  A DAT mutant with similar, but not identical characteristics to T62D-
hDAT is A559V-hDAT, a variant isolated from 2 male siblings with ADHD (Mazei-Robison et 
al., 2008).  Like T62D, A559V exhibits a baseline leak of DA but unlike T62D has normal 
[
3
H]DA uptake.  This difference may be because T62 lies near the permeation pathway and 
within the intracellular gating network while A559 appears to lie within TM 12 (Yamashita et 
al., 2005). 
Substrate movement and transporter conformations are driven by a network of molecular 
interactions.  Thr 62 is within a prime location to affect transporter orientation due to its 
proximity to TM 1a, which forms part of the permeation pathway (Shan et al., 2011; Yamashita 
et al., 2005).  This segment of the transmembrane domain is within an intracellular gating 
network (Kniazeff et al., 2008) that regulates conformational transitions in DAT (Shan et al., 
2011).  Previous in silico modeling of T62D-hDAT, in comparison to WT-hDAT, indicated a 
disruption of a functionally important microenvironment involving binding of T62 to other 




in intracellular loop (IL) 3 and K260 within IL2 resulting in a significant conformational change 
in which the cytoplasmic end of TM1 moves away from junctions with IL2 and IL3.  In the 
T62A-hDAT mutant, only the interaction with Y335 is lost which would account for its milder 
effects on DAT function (Guptaroy et al., 2009).  Notably, the Y335 and K260 residues have 
been implicated in the DAT intracellular gating network (Kniazeff et al., 2008). 
Other predominantly inward-facing DAT mutants, such as D345N (Chen et al., 2004a) and 
Y335A (Loland et al., 2002) have extremely low measureable rates of DA uptake, but baseline 
DA efflux had not been measured.  D345N appears to exist in an inward-facing conformation 
that cannot readily adopt an outward-facing conformation (Chen et al., 2004a).  In the bacterial 
Na
+
-dependent leucine transporter (LeuT), an R30A mutation affected the conformation of the 
intracellular network leaving the extracellular network largely unchanged (Zhao et al., 2010).  
This demonstrates, as do our data, that conformations in the transporter are flexible and that a 
mutation near one gate need not severely curtail function at the other gate. 




 across the membrane.  Measurement of 
DAT currents demonstrated that a greater quantity of ions travel across the membrane than 




 (Rudnick, 1998).  
Because DA efflux through DAT is enhanced at depolarized potentials (Khoshbouei et al., 2003) 
we proposed that expression of T62D could result in a higher resting membrane potential, as 
demonstrated in Xenopus oocytes for the inward-facing mutant Y335A-hDAT (Meinild et al., 




same extent which is likely the result of a common, substrate-independent leak current (Sonders 
et al., 1997).  Conversely, profound differences in current conductance in Xenopus oocytes 
expressing WT- and T62D-hDAT were found when measured in the absence versus presence of 
substrate.  No net current was detected in response to either DA or AMPH in T62D-hDAT.  This 
may imply that when T62D-hDAT is exposed to either DA or AMPH substrates the transporter 
more readily adopts a mode where the inward and outward flow of ions is equivalent.  A net flux 
of ions was restored in T62D-hDAT by the addition of Zn
2+
, which modifies transport through 
DAT by altering membrane potential through stimulating a chloride conductance (Meinild et al., 
2004; Pifl et al., 2009).  In heterologous HEK-293 cells or Xenopus oocytes, Zn
2+
 appears to 
stabilize an outward facing form of DAT, which results in a reduced influx of DA in WT, but 
enhanced influx in conformationally inward-facing mutants (Loland et al., 2002; Meinild et al., 




H]DA influx and AMPH-
induced DA efflux in T62D-hDAT-HEK cells (Guptaroy et al., 2009).  Zn
2+
 partially restored a 
substrate-induced current in T62D-hDAT-expressing Xenopus oocytes and enhanced DA 
currents in those expressing WT and T62A-hDAT.  However, with the accompaniment of Zn
2+
, 
DA (and AMPH) can induce an inward current in T62D-hDAT because the outward facing state 
is somewhat stabilized.  This allows an unequal shift in the direction of ion flow within T62D-
hDAT oocytes that involves more Na
+
 influx capable of provoking inward currents normally 
associated with substrate uptake (Sonders et al., 1997).  Under voltage-clamped conditions, 
substrate alone did not induce a detectable current in Xenopus oocytes containing the inward-






 alone induced a voltage-dependent current that was not further enhanced upon addition 
of substrate.  Substrate-induced inward currents in voltage-clamped T62A-hDAT oocytes were 
approximately half the magnitude of WT-hDAT oocytes.  This is in keeping with a half maximal 
reduction in the Vmax for [
3
H]DA uptake observed in T62A-hDAT cells, and our conclusion of 
the T62A mutation producing a transporter that is slower to transition between the outward and 
inward conformations (Guptaroy et al., 2009).  Even though oocytes were injected with equal 
concentrations of cRNA, we did not directly measure hDAT surface expression in the oocytes.  
Therefore, it cannot be ruled out that the reduction in the substrate-induced currents of T62A-
hDAT oocytes is due to fewer transporters expressed than in WT oocytes.  This possibility may, 
however, be unlikely since transfection of equivalent DNA construct concentrations in HEK 
293T cells showed similar levels of surface and total T62A and WT hDAT expression (Guptaroy 
et al., 2009) and we found similar amounts of [
3
H]DA uptake in WT- and T62A-hDAT 
expressing oocytes.  The discovery of varying current phenotypes in T62D-hDAT oocytes with 
and without substrate encouraged investigations into how the Thr 62 hDAT mutations would 
alter the extracellular and intracellular Na
+
 gradients required for DA uptake and efflux, 
respectively. 
Reduction of the transmembrane Na
+
 electrochemical gradient by increasing intracellular Na
+
 
levels or reducing extracellular Na
+
 concentration inhibits neurotransmitter uptake and 
simultaneously promotes reverse transport (Erreger et al., 2008; Khoshbouei et al., 2003; Liang 
and Rutledge, 1982; Raiteri et al., 1979; Zhen et al., 2005).  As a substrate, AMPH increases the 
inward transport of both DA and Na
+
.  Evidence suggests that the build-up of Na
+




cytosolic face of the transporter underlies the ability of DAT to adopt an inward-facing 
conformation (Liang and Rutledge, 1982; Raiteri et al., 1979).  Khoshbouei et al. (2003) 
demonstrated that direct increases in intracellular Na
+
 stimulates carrier-mediated DA efflux and 
proposed that an AMPH-induced inward current increases intracellular Na
+
 availability to DAT.  
Our data demonstrated that DA efflux in T62D-hDAT was insensitive to changes in the Na
+
 
electrochemical gradient, suggesting that the T62D-hDAT conformation is already in a Na
+
-
receptive orientation.  The fact that accumulation of the ASP
+
 substrate that is not subject to 
reverse transport, in T62D-hDAT is equivalent to WT hDAT suggests that the Na
+
-primed 
conformation of the inward-facing mutant does not preclude adoption of the outward-facing form 
which binds substrate.  We have previously demonstrated that the Km for [
3
H]DA at the inward-
face in T62D hDAT is significantly less than that of WT (Guptaroy et al., 2009).  Therefore, the 
Na
+
-primed conformation of DAT is able to readily rebind DA, such that it is unlikely that empty 
transporter returns to the surface. 
The Na
+
-sensitivity of other inward-facing DAT mutants has not routinely been measured.  The 
A559V DAT variant demonstrated normal DA uptake in the face of greater DA efflux that was 
due to an enhanced sensitivity to intracellular Na
+
 (Mazei-Robison et al., 2008).  A key 





while T62D-hDAT was unresponsive to even partial changes in the 
transmembrane Na
+
 gradient.  Nonetheless, the similarities underscore the importance of the 
sodium gradient in maintaining the conformational states of DAT.  Another similarity between 




Robison et al. (2008) measured this inhibition in cells containing A559V hDAT but not in WT, 
likely because their efflux measurements were conducted with high intracellular [Na
+
] 
conditions.  However, AMPH will inhibit transporter-stimulated DA efflux in WT when Nae
+
 is 
zero.  The diminution of DA efflux in WT hDAT under low Nae
+
 conditions was also noted by 
Pifl et al. (1997).  Therefore, even though AMPH appears to bind to an inward-facing form of 
DAT (T62D-hDAT), as we demonstrated previously (Guptaroy et al., 2011; Guptaroy et al., 
2009), it acts as an inhibitor rather than a substrate. 
This study has uncovered novel attributes between the T62A and T62D-hDAT mutations.  
T62A-hDAT cells maintain a need for the Na
+
 gradient to induce basal and AMPH-stimulated 
DA release that is not observed in T62D-hDAT HEK cells.  Strikingly, the high level of basal 
DA efflux initially observed in T62D-hDAT at any Na
+
e concentration is comparable to the DA 
efflux states of WT-hDAT induced either by removal of Na
+
e or AMPH stimulation at 125 mM 
Na
+
e.  It is therefore plausible that the inward facing orientation of T62D-hDAT represents a 
Na
+
-primed conformational state in which reverse transport in favored.  Taken together, our data 
place importance on the molecular interactions between residues differentially influencing the 
efflux properties of the transporter.  The T62D-hDAT and other transporter mutants can serve as 
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A recurring theme of the work in this dissertation is the influence of conformation on transporter 
activity.  Transporter orientation is driven by formation, stabilization, and disruption of 
molecular interactions to facilitate substrate translocation.  Understanding the mechanism of 
AMPH action on transporter reversal has clinical relevance.  As a substrate of DAT & NET, the 
end result of AMPH transport is the ‘reverse’ transport of DA and NE into the extracellular 
space.  This action involves transition of inward- to outward-facing conformations.  My 
characterization of NET and DAT mutants discussed in preceding chapters adds to our 
knowledge on the relation of conformational shifts to alterations in activity, and improves 
understanding on the molecular basis of transporter function and potential drug action.  In this 
final dissertation chapter additional points of investigation will be discussed for the N-terminal 
Thr NET and/or DAT mutants.  
Intracellular Gating and Reverse Transport  
Mutation of the Proposed DAT Y335 Binding Partner 
Molecular simulation studies in the literature have provided much insight on the outward to 
inward translocation of substrate.  However, less is known about details of the reverse, inward to 
outward motions.  Our analysis showed that the T62D-hDAT inward facing mutant has 
profoundly altered transporter activity and function as exemplified by the enhanced DA affinity 




(Guptaroy et al., 2011).  The T62D-hDAT mutant displays elevated basal (unstimulated) DA 
efflux and is insensitive to further DA release by AMPH (Guptaroy et al., 2009).  My data 
suggest the preferred conformation of the T62D mutation is an efflux-favored, Na
+
 primed state 
of the transporter (Chapter 3). 
Through molecular modeling of the DAT intracellular gating network, it is proposed that binding 
of the N-terminal Thr 62 residue with Tyr 335 of TM 6 enables opening of the intracellular gate 
and assumption of the inward facing orientation (Shan et al., 2011).  The T62D mutation results 
in a loss of the connection of Y335 with T62, along with disruption of other interactions with 
residues at or near the intracellular gating network (Guptaroy et al., 2009).  The Y335A-hDAT 
mutant developed by the Gether laboratory Loland et al. (2002) has also been deemed an inward 
facing transporter due to the impaired DA uptake and changed binding profile for substrates 
(↓Ki) and inhibitors (↑Ki) in [
3
H]DA uptake competitions.  However, an effect of the Y335A 
mutation on DA efflux was not reported (Loland et al., 2002).  The impact of the Tyr 335 residue 
and its interaction with Thr 62 on reverse transport is worth exploring.  This was approached by 
creating the Y335F-hDAT mutant.  The phenylalanine substitution of tyrosine is a relatively 
subtle amino acid change that should disturb the T62 and Y335 intracellular connection.  This 
mutant was stably expressed in HEK-293 cells for analysis of [
3





DA Uptake and Efflux in the Y335F-hDAT Mutant 
Preliminary results from [
3
H]DA saturation assays revealed an approximate 50% reduction in the 
Vmax (p = 0.0002) and unchanged Km (p = 0.6098) for DA uptake in Y335F-hDAT HEK cells 




H]DA uptake saturation in WT- and Y335F-hDAT HEK cells.  Uptake of 10 nM [
3
H]DA 
was measured in the presence of increasing unlabeled DA concentrations.  The assay was conducted for 3 
min at RT, and non-specific uptake was measured in the presence of 100 µM cocaine after a 10 min 
preincubation.  Vmax (pmols) and Km (µM) values were determined from the nonlinear regression curve fit 
analysis using GraphPad Prism 6 software.  Data are from 1 (WT) or 2 (Y335F) experiment performed in 
triplicate. 
I also performed pilot studies measuring the effects of extracellular Na
+
 on basal and AMPH-
induced DA efflux.  The plated [
3
H]DA efflux assay (detailed in Chapter 3) was used to measure 
basal DA efflux at 10 and 20 min, followed by DA efflux after a 5 min AMPH (10 µM) 
stimulation.  [
3
H]DA efflux was determined in normal (125 mM) and complete substitution (0 
mM) of extracellular Na
+
.  After preloading cells with 0.5 µM [
3




in aliquots of assay buffer that were collected and replaced at the indicated time points.  For 0 
mM Na
+
, NaCl in the assay buffer was replaced with 125 mM NMDG-Cl.  
 
Figure 4-2. Effects of extracellular Na
+
 replacement on basal and AMPH-induced [
3
H]DA efflux.   
(left) WT- and (right) Y335F-hDAT HEK cells were preloaded with 0.5 µM [
3
H]DA for 20 min at RT.  DA 
efflux was measured at normal, 125 mM Na
+
 (closed symbols) and 0 mM Na
+
 (open symbols).  WT data 
are from a single experiment performed in quadruplicate.  Y335F data are from 1 or 2 experiments 
performed in 3-8 replicates. 
[
3
H]DA efflux data are expressed as a percent of the total DA within the cell.  However, there 
was a 45% reduction in the amount of total DA taken up by Y335F-hDAT cells compared to WT 
(average total radioactive cpm in WT = 30796 and Y335F = 14004).  This is in line with the 
observed change in Vmax for DA uptake (Figure 4-1).  Fitting with the lower measured [
3
H]DA 
uptake, baseline DA release appeared higher in Y335F- than WT-hDAT cells.  Nonetheless, 
removal of extracellular Na
+
 increased baseline DA efflux in both cell types.  This differed from 
the Na
+
 independence of elevated basal DA efflux observed in T62D-hDAT cells (Chapter 3).  
While inhibition of DA efflux with AMPH treatment at 0 mM Na
+




AMPH-stimulation of DA efflux at 125 mM Na
+
e was negligible in Y335F-hDAT versus WT 
cells (Figure 4-2). 
The Brandel superfusion assay is useful to further validate AMPH’s effect (at normal Na
+
) in the 
Y335F-hDAT mutant cell line.  Reuptake is less of a factor in the superfusion assay, which 
offers improved resolution for measuring carrier-mediated release.  In this technique cells 
preloaded with DA are placed into superfusion chambers.  KRH buffer is perfused over the cells 
for 30 min to establish a steady baseline.  Afterward, five 1-min fractions of perfusate are 
collected (flow rate 0.8 ml/min), followed by 2 fractions of 10 µM AMPH stimulation, then 6 
additional KRH fractions.  The amount of DA within each fraction is measured using HPLC with 
electrochemical detection by comparison to a standard DA curve.  The data are represented as 
the pmol of DA per mg of protein per 1 min and normalized to the total DA.  Cells are 
maintained at 37°C throughout the entire assay. 
 
Figure 4-3. Brandel superfusion to measure AMPH-induced DA efflux in WT- and Y335F-hDAT 
HEK cells preloaded with 15 µM DA for 30 min at 37°C.  After equilibration, the first fraction is 
discarded and 5 min baseline fractions are collected.  Cells are perfused with 10 µM AMPH at fractions 7 
& 8 then changed back to KRH buffer for the remaining collection period.  Data are from a single 




The total DA was nearly 40% less in Y335F- versus WT-hDAT cells (WT = 319.7 and Y335F = 
123 pmol/mg protein).  After normalization to the total DA, DA efflux induced by AMPH 
appeared lower in Y335F-hDAT cells (Figure 4-3).   
In the final pilot experiment total DA loading in Y335F- to WT-hDAT cells was standardized.  
This was done by incubating cells with a lower DA concentration (5 µM) for a longer time 
period (3 hr).  AMPH-induced DA efflux was measured as stated above.  
 
Figure 4-4. AMPH-induced DA efflux in WT- and Y335F-hDAT HEK cells preloaded with 5 µM DA 
for 180 min at 37°C.  Superfusion was conducted as stated in Figure 4-3.  Data are from a single 
experiment performed in duplicate.   
 
With these preloading conditions, the total DA in Y335F- was more comparable to WT-hDAT 
HEK cells (WT = 136 and Y335F = 121 pmol DA/mg protein).  Despite the elevated baseline 
DA efflux in WT cells, there was a clear loss of AMPH-induced DA efflux in the Y335F-hDAT 




My preliminary data characterizing the Y335F-hDAT mutant points to the importance of this 
residue in AMPH-induced reverse transport of DA.  The pattern of DA efflux seen with Y335F 
thus far differs from that seen in either T62A or T62D-hDAT mutants.  In a certain sense, the 
Y335F mutation seems to be a hybrid of the functional effects elicited by the Thr 62 mutations 
but shares more characteristics with T62A- than T62D-hDAT.  The reduced DA uptake in 
Y335F and influence of the Na
+
 gradient on DA efflux in Y335F were similar to T62A-hDAT.  
The ability of AMPH to elicit efflux in Y335F-hDAT was severely compromised but the data in 
Figure 4-3 suggest that loading with a high concentration of DA (15 µM) might permit 
stimulated efflux.  The Y335F mutation is posited to yield a mutant with normal DA intake, but 
have defective AMPH-stimulated DA output through the transporter.  This could likely occur 
through the conservation of interactions involved in extracellular gating with modest disruption 
of intracellular connections that mediate reverse transport.  On the contrary, the T62D mutation 
perturbs the intracellular network to a greater extent, impacting both basal and AMPH-induced 
reverse transport. 
Additional repetitions of these Y335F-hDAT pilot studies as well as analyses of DA uptake with 
Na
+
 replacement would be needed to strengthen this hypothesis.  Furthermore, in order to rule 
out variations in transporter expression, surface expression of the Y335F hDAT mutant using 
biotinylation or binding of WIN 35,428 would need to be evaluated.  This should be performed 





Proposed Alteration of Transport Schematic in T62D-hDAT 
Though they tend to oversimplify the many intricacies of the transport process, schematics are 
useful to depict the transitions involved in the transport cycle under normal and modified 
conditions (Gnegy, 2003; Shi et al., 2008).  The kinetics of transporter current measurements 
have been effectively correlated to the steps of the alternating access model of transport, further 
validating schematic representations (Bulling et al., 2012; Erreger et al., 2008).  The 
conformational shifts from the T62D and Y335F hDAT mutations would lead to changes in the 
transport cycle.  These proposed changes are highlighted in Figure 4-5 to explain the functional 
differences of the DAT mutants.   
 
 Figure 4-5. Schematic of transport cycle in WT-, T62D- and Y335F hDAT.  Normal transport cycle in 




 independent DA 
 efflux in T62D (C), and reduced AMPH-induced DA release in Y335F (D).  To = outward transporter, Ti = 





Under normal conditions, empty WT transporter oscillates between  binding co-transported ions 
and substrate that stimulates a rapid transition to the inward facing orientation where transporter 
contents are released  before return of the empty inward transporter to the outward orientation 
(Figure 4-5A).  As depicted in Figure 4-5B, carrier-mediated DA efflux occurs in WT-hDAT 
when AMPH (or low Na
+
e) stimulates an increase of  intracellular Na
+
 levels, and “places DAT 
in Na
+
-exchange mode—where occupied carrier rearranges to outward facing more rapidly than 
empty carrier” (Erreger et al., 2008).  T62D-hDAT is depicted as existing in a Na
+
-primed mode 
with pronounced inward to outward rearrangement of occupied carrier in a manner that is not 
driven by intracellular Na
+
 (small font Na
+
 ions) (Figure 4-5C ).  The Y335F-hDAT mutation 
may result in a reduction of DA occupied DAT cycling to the outward facing orientation in 
response to AMPH.  However, high intracellular Na
+
 (e.g. during removal of Na
+
e) still 
stimulates release in the absence of AMPH (Figure 4-5D). 
Though not included on the schematic above, Cl
-
 is important for substrate transport substrate 
binding and unbinding (Zomot et al., 2007), DA uptake and inward currents (Ingram et al., 
2002), and DA efflux (Diliberto et al., 1989).  I have performed preliminary experiments 
examining the importance of extracellular Cl
-
.  Reducing extracellular Cl
-
 modestly increased 
basal DA efflux in both WT and T62D-hDAT.  Therefore, DA efflux in T62D-hDAT did not 
appear to be insensitive to Cl
-
 as it was to Na
+
.  Additionally, manipulating the extracellular Cl
-
 
did not restore the ability of AMPH to elicit DA efflux in T62D-hDAT.  Further studies 
comparing Y335F-, T62A-, and T62D-hDAT mutants should incorporate effects Cl
-
 substitution 






Multiple studies have implicated phosphorylation in the regulation of transporter functions.  The 
highly conserved DAT Thr 62 residue and NET Thr 58 are a putative phosphorylation sites for 
protein kinases such as PKA and PKC (Giros and Caron, 1993; Vaughan, 2004; Volz and 
Schenk, 2005).  Because the RETW sequence is conserved in monoamine transporters in which 
AMPH is a substrate, and because the Thr within the sequence is a putative phosphorylation site, 
we mutated Thr to Asp to give a phosphorylation-mimicking state and to Ala to represent a non-
phosphorylatable state.  It is not currently known whether direct phosphorylation occurs at Thr 
62 in DAT or Thr 58 in NET.  Phosphorylation of DAT has been demonstrated to occur within 
N-terminal serines, up through ser53 (Vaughan, 2004).  Although this phosphorylation may be 
important for regulation of DAT function, these serines do not exist in NET, and would not play 
a role in AMPH function in that transporter.  Our data would suggest that if Thr 62 or Thr 58 
were phosphorylated in response to AMPH or a change in the electrochemical gradient to Na
+
, 
that it would be a fleeting phosphorylation.  Although it is important to discern whether this 
residue is actually phosphorylated during the transport cycle, the TD mutation has proven 
highly useful as a means to help us elucidate the DAT and NET functions and transport cycle. 
It is possible that phosphorylation at the Thr within the RETW sequence could contribute to 
AMPH function.  Phosphorylation has been associated with DAT- and NET-mediated DA efflux 




cells (Park et al., 2003).  Moreover, AMPH-induced DA release through both DAT (Kantor and 
Gnegy, 1998) and NET (Kantor et al., 2001) requires PKC, particularly PKCβ as seen in cell 
systems and striatal preparations (Johnson et al., 2005; Kantor and Gnegy, 1998; Kantor et al., 
2001).  The DAT N-terminus influences AMPH-induced DA efflux as indicated by a significant 
reduction in DA release in DAT lacking the first 22 amino acids (ΔN22-DAT) (Khoshbouei et 
al., 2004), in which phosphorylation by PMA-stimulated PKC activation is reduced (Granas et 
al., 2003).  Despite evidence for the first 22 DAT amino acids taking part in PKC regulation of 
AMPH-induced DA efflux, other N-terminal residues can play role as well.  Recently, loss of 
direct phosphorylation at rat DAT (rDAT) Thr 53 (T53-rDAT) has been associated with reduced 
DA uptake and MPP
+
 efflux (Foster et al., 2012).  Determining the phosphorylation state at T62-
hDAT and T58-hNET sites would help elucidate whether increased efflux observed in the 
inward facing T62D-hDAT is solely an attribute of conformational disruptions in the mutant or if 
actual Thr 62 phosphorylation is a component as well, which could have direct effects or indirect 






Trafficking and Inward Transport 
Although PKC activation influences DAT uptake and surface expression in some instances 
(Chen et al., 2009; Furman et al., 2009; Vaughan et al., 1997), evidence also suggests DAT 
internalization occurs independently of PKC phosphorylation (Granas et al., 2003).  The first 22 
amino acids have been implicated in DAT internalization effects.  However the involvement of 
other N-terminal residues may depend on the conformational state of the transporter.  A mix of 
mutations (that included the R60 and W63 of RETW sequence) that was reported to disrupt the 
outward-facing orientation resulted in increased endocytosis, suggesting single mutations alone 
may not be disruptive to the transporter endocytic signals (Sorkina et al., 2009).  However, in an 
investigation of phosphoacceptor sites important for transporter regulation, Lin et al. (2003) 
showed the single T62A mutation or a combination of other mutated hDAT sites can 
differentially affect kinase effectors like PI3K versus PKC.  There was no difference in the 
percentage of transporter expressed at the surface between the T62A or T62D mutants in 
either hNET or hDAT (Guptaroy et al., 2011; Guptaroy et al., 2009), which may imply 
constitutive trafficking is unaffected by the Thr mutations.  Further experiments could 
investigate whether the mutations effect the endocytic signal with other factors like time course 
(acute versus long term) and drug treatment (PMA or AMPH stimulation).  
Protein interactions 
The investigations within my dissertation have dealt with transporters expressed in cell-based 




is also crucial to think about transporters in the context of their physiological environment.  DAT 
interacts with a variety of proteins (Torres, 2006) and mutations in Thr 62 hDAT and Thr 58 
hNET could alter function by altering requisite protein-protein interactions.  Two proteins in 
particular which bind to the N-terminus of DAT and significantly alter DAT function are 
syntaxin 1A and the D2 DA autoreceptor.  Another protein which binds to the N-terminus of 
DAT and thus provides a means to significantly alter DAT function is RACK1 (Lee et al., 2004; 
Ron et al., 1994), which is a docking protein for PKC, especially PKCII (Ron et al., 1999). 
Syntaxin 1A and Dopamine Autoreceptor 
Syntaxin is a presynaptic SNARE protein well known for its function in docking of synaptic 
vesicles for neurotransmitter release (Sudhof, 2004).  However syntaxin1A appears to play a 
more general role in docking of small vesicles, such as those containing NET and DAT, as well 
as synaptic vesicles (Quick, 2006).  Syntaxin 1A directly interacts with the first 42 residues of 
NET (Sung et al., 2003) and 33 residues of DAT (Binda et al., 2008).  Syntaxin 1A alters both 
surface expression and function of DAT and NET but its actions are complex.  Overexpression 
of syntaxin 1A and NET increases surface NET yet limits NET function (Sung et al., 2003); 
while overexpression of syntaxin 1A with DAT decreases surface DAT yet enhances AMPH-
induced DA efflux.  Since phosphorylation and transporter functions and protein-protein 
interactions are intertwined to some degree, it would be instructive to probe the effect of 




Along with DAT, the dopamine D2-like autoreceptor (D2R) is a key protein for controlling 
extracellular DA levels, and DAT coupling to D2R increases DAT activity.  Similar to syntaxin 
1A, a direct interaction has been established between residues 1-26 of the DAT N-terminus and 
residues 311-344 of D2 autoreceptor 3
rd
 extracellular loop (Lee et al., 2007).  Coupling of 
DAT/D2R in co-transfected HEK 293 cells increased surface DAT expression (Lee et al., 2007).  
PKCβ is needed for D2R activation of DAT trafficking (Chen et al., 2013).  It is very likely the 
conformation of DAT would change the coupling of DAT to D2Rs, and warrants exploration in 
the Thr62 hDAT mutants. The A559V hDAT variant, which has intact DA uptake but irregular 
DA efflux (Mazei-Robison et al., 2008) shares similar features with our T62D-hDAT mutant (as 
discussed in Chapter 3), and may also exist in an inward-facing conformation.  Recently the 
efflux state of A559V hDAT was found to be dependent on N-terminal phosphorylation via 
CaMKII, and was inhibited by the D2-like receptor antagonist raclopride (Bowton et al., 2010).  
Such studies surveying protein-protein interactions in the NET and DAT N-terminal Thr mutants 
would aid in determining if orientation influences the association of transporter proteins and their 
resulting functional effects. 
An Experimental Behavioral Model of T62D-hDAT 
Use of transgenic mouse models, usually of specific gene knockouts, has been a staple method of 
studying the action and behaviors of addictive drugs (Sora et al., 2010).  Our understanding of 
psychostimulant action on monoamine transporters (DAT, NET, and SERT) and their link to 
disease states has been greatly advanced by the use of mice with genetic deletions of the 




phenotypes like reduced DA clearance and hyperactivity (Giros and Caron, 1993) that bear 
similarity to ADHD symptoms.  The DAT knockout mouse has been proposed as a model for 
ADHD, but global deletion and dysfunction of DAT is an unlikely attribute to the disease 
(Gainetdinov and Caron, 2003).  This is exemplified by the normal DA uptake function but 
enhanced DA reverse transport expressed by the rare A559V genetic variant of DAT found in 
two siblings with ADHD (Mazei-Robison et al., 2008).  Therefore, it is important to develop 
additional animal models that better represent impairments of transporter functions. 
A relatively new behavioral assay for AMPH action was discovered in Caenorhabditis elegans 
called swim induced paralysis (SWIP).  Excessive synaptic DA results in paralysis of C. elegans 
when it is placed in water.  AMPH-induced SWIP in WT C. elegans requires dopamine receptors 
and DA efflux through the C. elegans DA transporter (DAT-1) (Carvelli et al., 2010).  The C. 
elegans system could be used to develop a behavioral phenotype for the T62D-hDAT mutant 
with the SWIP assay.  This would require expression of fluorescently tagged T62D-hDAT in 
DAT-1 knockout (dat-1) C. elegans to identify organisms containing the hDAT mutant.  The 
enhanced constitutive DA efflux in T62D should induce SWIP without further stimulation of 
paralysis by AMPH.  SWIP in T62D C. elegans would resemble the behavior of AMPH treated 
WT C. elegans or the intrinsic SWIP in dat-1 C. elegans.  Positive results would confirm the 
notion of the T62D-hDAT serving as a conformational representation of AMPH induced changes 




The T62D-hDAT has potential application as a mouse model of diseases involving enhanced DA 
overflow in the synapse.  The proposed elements discussed earlier such as protein interactions 
and trafficking can be studied in a native environment.  More importantly such an animal model 
may be useful in a variety of physiological relevant studies such as AMPH sensitization, 
development of tolerance to psychostimulants, preferences for additional drugs of abuse (e.g. 
alcohol, nicotine, opioids), or cognitive impairments. 
Conclusions 
The N-terminal Thr 62 and Thr 58 residues of hDAT and hNET respectively, are important 
regulatory sites of transporter orientation.  Transporter conformational shifts are instrumental to 
carrying out the movement of neurotransmitter from one side of the membrane to the next.  This 
is especially important for clearance of neurotransmitter from the extracellular space.  Yet on the 
other hand, is also a key part of intracellular transporter-mediated neurotransmitter release to 
maintain neuronal tone or in response to drug action.   
Alanine or aspartate substitutions of the Thr sites affect the equilibrium of transporter 
conformation and consequently impacts function.  The TD mutant NET and DAT preferred 
the inward facing conformation that enhanced basal DA reverse transport, abrogated [
3
H]DA 
uptake and AMPH’s effect of efflux stimulation.  The work of this dissertation further analyzed 
alterations in hNET and hDAT properties elicited by the Thr mutations.  Findings of variations in 
ligand interactions were presented in chapter 2.  Substrate affinity was significantly enhanced in 




unaffected in hNET mutants, but altered in hDAT mutants in a manner influenced by the 
inhibitor structure.  Functional characterization of the T62 hDAT mutants was continued in 
chapter 3.  Significant discoveries were 1) normal transporter intake, seen by accumulation of 
fluorescent substrate ASP
+
; and 2) a Na
+
-independence of the elevated DA efflux in T62D-
hDAT.  My results emphasize the variety of consequences conformational change can have on 
transporter functions.  The preliminary results and ideas presented in the final chapter extend the 
investigations of T62D-hDAT inward facing mutant towards an additional amino acid binding 
partner, protein-protein interactions, and application to behavior model.  The use of transporter 
mutants will continue to improve knowledge of transporter mechanisms and the amino acids 
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